<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101830</article-id><article-id pub-id-type="doi">10.7554/eLife.101830</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101830.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tanaka</surname><given-names>Toru</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1054-9211</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Sasaki</surname><given-names>Naoto</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7760-6129</contrib-id><email>n-sasaki@kobepharma-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Krisnanda</surname><given-names>Aga</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-6417-2738</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Amin</surname><given-names>Hilman Zulkifli</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="pa3">#</xref><xref ref-type="fn" rid="pa4">¶</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Horibe</surname><given-names>Sayo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4111-2426</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Matsuo</surname><given-names>Kazuhiko</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5782-5300</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hirata</surname><given-names>Ken-ichi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa5">**</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Takashi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8493-899X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rikitake</surname><given-names>Yoshiyuki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7207-4656</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00088z429</institution-id><institution>Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University</institution></institution-wrap><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03tgsfw79</institution-id><institution>Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kt9ap64</institution-id><institution>Division of Chemotherapy, Faculty of Pharmacy, Kindai University</institution></institution-wrap><addr-line><named-content content-type="city">Higashi-osaka</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Escande</surname><given-names>Carlos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dpm2z73</institution-id><institution>Institut Pasteur de Montevideo</institution></institution-wrap><country>Uruguay</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>The University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Laboratory for inflammation and regeneration, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Integrated Clinical Education Center, Kobe University Hospital, Kobe, Japan</p></fn><fn fn-type="present-address" id="pa3"><label>#</label><p>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan</p></fn><fn fn-type="present-address" id="pa4"><label>¶</label><p>Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia</p></fn><fn fn-type="present-address" id="pa5"><label>**</label><p>Department of Cardiology, Kakogawa Central City Hospital, Kakogawa, Japan</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>07</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP101830</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-08-16"><day>16</day><month>08</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-08-19"><day>19</day><month>08</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.08.16.608245"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-14"><day>14</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101830.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-27"><day>27</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101830.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-02"><day>02</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101830.3"/></event></pub-history><permissions><copyright-statement>© 2024, Tanaka, Sasaki et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Tanaka, Sasaki et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101830-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-101830-figures-v1.pdf"/><abstract><p>Chronic inflammation via dysregulation of T cell immune responses is critically involved in the pathogenesis of atherosclerotic cardiovascular disease. Improving the balance between proinflammatory T cells and anti-inflammatory regulatory T cells (Tregs) may be an attractive approach for treating atherosclerosis. Although C-C chemokine receptor 4 (CCR4) has been shown to mediate the recruitment of T cells to inflamed tissues, its role in atherosclerosis is unclear. Here, we show that genetic deletion of CCR4 in hypercholesterolemic mice accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype. This was associated with the augmentation of proinflammatory T helper type 1 (Th1) cell responses in peripheral lymphoid tissues, para-aortic lymph nodes, and atherosclerotic aorta. Mechanistically, CCR4 deficiency in Tregs impaired their suppressive function and tended to inhibit their migration to the atherosclerotic aorta, and subsequently augmented Th1 cell-mediated immune responses through defective regulation of dendritic cell function, which accelerated aortic inflammation and atherosclerotic lesion development. Thus, we revealed a previously unrecognized role for CCR4 in controlling the early stage of atherosclerosis via Treg-dependent regulation of proinflammatory T cell responses. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>atherosclerosis</kwd><kwd>T cell</kwd><kwd>chemokine receptor</kwd><kwd>inflammation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>KAKENHI</institution></institution-wrap></funding-source><award-id>JP21K08042</award-id><principal-award-recipient><name><surname>Sasaki</surname><given-names>Naoto</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008667</institution-id><institution>SENSHIN Medical Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sasaki</surname><given-names>Naoto</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008664</institution-id><institution>Ono Medical Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sasaki</surname><given-names>Naoto</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Novartis Japan</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sasaki</surname><given-names>Naoto</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010793</institution-id><institution>Pfizer Japan</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rikitake</surname><given-names>Yoshiyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004948</institution-id><institution>Astellas Pharma</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rikitake</surname><given-names>Yoshiyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>KAKENHI</institution></institution-wrap></funding-source><award-id>JP24K11301</award-id><principal-award-recipient><name><surname>Sasaki</surname><given-names>Naoto</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>CCR4 expression in Tregs is critical for limiting proinflammatory Th1 cell-mediated immune responses and atherosclerosis by maintaining the suppressive and migratory functions of Tregs.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Severe cardiovascular diseases, including ischemic heart disease and stroke, occur in patients with atherosclerosis and are major causes of mortality worldwide. Despite state-of-the-art intensive treatment, patients at high risk of atherosclerotic diseases have considerable residual risk, which could be partly related to vascular inflammatory responses (<xref ref-type="bibr" rid="bib38">Weber et al., 2023</xref>). Notably, recent clinical trials have provided evidence that anti-inflammatory therapies could be potentially novel approaches for preventing cardiovascular diseases in patients with a past disease history, although overall mortality has not improved (<xref ref-type="bibr" rid="bib25">Ridker et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Tardif et al., 2019</xref>).</p><p>Chronic aortic inflammation via T cell-mediated immune dysregulation has been shown to be critically involved in the development of atherosclerosis (<xref ref-type="bibr" rid="bib26">Roy et al., 2022</xref>). Single-cell proteomic and transcriptomic approaches have revealed that activated and differentiated T cells are the major immune cells infiltrating human carotid artery plaques (<xref ref-type="bibr" rid="bib10">Fernandez et al., 2019</xref>), indicating the involvement of T cell-mediated immunoinflammatory responses in atherosclerotic plaque development in humans. A recent clinical trial provided evidence for the increased risk of atherosclerotic cardiovascular disease events in cancer patients treated with immune checkpoint inhibitors (<xref ref-type="bibr" rid="bib7">Drobni et al., 2020</xref>), confirming the critical role of effector T cell (Teff) immune responses in the development of human atherosclerotic disease. Teffs, including T helper type 1 (Th1) cells, play a proatherogenic role by producing proinflammatory cytokines, including interferon (IFN)-γ (<xref ref-type="bibr" rid="bib13">Gupta et al., 1997</xref>; <xref ref-type="bibr" rid="bib3">Buono et al., 2005</xref>). A recent translational study demonstrated that anti-CXC-motif-chemokine receptor 3 autoantibodies, which reflect Th1 cell-mediated responses, can be a novel biomarker and an inflammatory risk factor for cardiovascular morbidity and mortality beyond traditional risk factors, indicating the possible proatherogenic role of Th1 cells in humans (<xref ref-type="bibr" rid="bib22">Müller et al., 2023</xref>). On the other hand, several subsets of regulatory T cells (Tregs), including forkhead box P3 (Foxp3)-expressing Tregs, play an anti-atherogenic role by suppressing Teff-mediated immunoinflammatory responses or reducing plasma atherogenic lipoprotein levels (<xref ref-type="bibr" rid="bib1">Ait-Oufella et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Sasaki et al., 2009</xref>; <xref ref-type="bibr" rid="bib17">Klingenberg et al., 2013</xref>). A number of approaches to dampening proatherogenic Th1 cell responses or augmenting atheroprotective Treg responses have been reported to be effective for the treatment and prevention of atherosclerosis in experimental mouse models (<xref ref-type="bibr" rid="bib32">Tanaka et al., 2021</xref>). Despite accumulating evidence for the critical role of the Th1 cell/Treg balance in atherosclerosis, how the balance of these T cell populations is regulated in lymphoid tissues and atherosclerotic lesions to control atherosclerosis is unclear.</p><p>Various immune cells, including T cells and monocytes, migrate to the aorta via interactions between chemokines and their specific chemokine receptors and are critically involved in the process of atherosclerosis (<xref ref-type="bibr" rid="bib23">Noels et al., 2019</xref>). However, few reports have identified a chemokine system that prevents atherosclerosis by improving the Th1 cell/Treg balance in lymphoid tissues and atherosclerotic lesions. C-C chemokine receptor 4 (CCR4) is expressed on several T cell subsets, including T helper type 2 (Th2) cells, T helper type 17 (Th17) cells, skin-homing T cells, and Tregs, but not on proatherogenic Th1 cells (<xref ref-type="bibr" rid="bib12">Griffith et al., 2014</xref>). CCR4 is a highly specific receptor for two CC chemokine ligands CCL17 (thymus- and activation-regulated chemokine) and CCL22 (macrophage-derived chemokine) (<xref ref-type="bibr" rid="bib41">Yoshie, 2021</xref>), which were shown to be expressed in mesenteric lymph nodes (LNs) in a mouse model of inflammatory bowel disease (<xref ref-type="bibr" rid="bib42">Yuan et al., 2007</xref>) and lung tissues affected by allergic airway inflammation (<xref ref-type="bibr" rid="bib8">Faustino et al., 2013</xref>). These chemokines play a role in guiding CCR4<sup>+</sup> T cells to the inflammatory sites with abundant expression of these chemokines (<xref ref-type="bibr" rid="bib4">Campbell et al., 1999</xref>; <xref ref-type="bibr" rid="bib21">Montane et al., 2011</xref>). Previous experimental studies have suggested that the CCL17/CCL22–CCR4 axes protect against inflammatory autoimmune diseases partly by promoting Treg accumulation in target tissues (<xref ref-type="bibr" rid="bib42">Yuan et al., 2007</xref>; <xref ref-type="bibr" rid="bib8">Faustino et al., 2013</xref>). The expression of CCL17 and CCL22 was also observed in human and mouse atherosclerotic lesions (<xref ref-type="bibr" rid="bib11">Greaves et al., 2001</xref>; <xref ref-type="bibr" rid="bib37">Weber et al., 2011</xref>; <xref ref-type="bibr" rid="bib16">Kimura et al., 2015</xref>). Although the disruption of the CCL17/CCL22–CCR4 axes did not affect the development of advanced atherosclerotic lesions or the proportion of Tregs in peripheral lymphoid tissues in atherosclerosis-prone mice fed a high-cholesterol diet (<xref ref-type="bibr" rid="bib37">Weber et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Döring et al., 2024</xref>), its effect on the early stage of atherosclerosis and Treg responses has not been investigated.</p><p>Here, we investigated the role of CCR4 in the development of early atherosclerotic lesions and the underlying mechanisms in CCR4-deficient (<italic>Ccr4</italic><sup>-/-</sup>) mice on an apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) background fed a standard chow diet, with a particular focus on CD4<sup>+</sup> T cell immune responses.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>CCR4 is predominantly expressed on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs, and the ligands CCL17 and CCL22 are expressed in peripheral LNs and atherosclerotic lesions</title><p>To evaluate the expression levels of CCR4 on CD4<sup>+</sup> T cells under normocholesterolemic or hypercholesterolemic conditions, we performed flow cytometric analysis of peripheral LNs, spleen, and para-aortic LNs from wild-type, <italic>Apoe</italic><sup>-/-</sup>, and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Notably, CCR4 expression was expressed on approximately 15–25% of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs from wild-type or <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1A–C</xref>), while CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs from these mice expressed CCR4 at markedly lower levels, suggesting that CCR4 is predominantly expressed on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and that hypercholesterolemia does not affect CCR4 expression. We also examined CCR4 expression on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in the atherosclerotic aorta of <italic>Apoe</italic><sup>-/-</sup> mice and consistently found that CCR4 expression in CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs was much higher than that in CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1D</xref>).</p><p>As CCL17 and CCL22, known as specific ligands for CCR4, are highly expressed by dendritic cells (DCs) in LNs (<xref ref-type="bibr" rid="bib2">Alferink et al., 2003</xref>; <xref ref-type="bibr" rid="bib34">Tang and Cyster, 1999</xref>), we examined their expression in the peripheral LNs of wild-type, <italic>Apoe</italic><sup>-/-</sup>, and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice by immunohistochemistry. As expected, clear expression of these chemokines was observed in the peripheral LNs of wild-type, <italic>Apoe</italic><sup>-/-</sup>, and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref>). We also examined the expression of CCL17 and CCL22 in the aorta of these mice by immunohistochemistry. CCL17 expression was detected in the atherosclerotic lesions of <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, and some lesional MOMA-2<sup>+</sup> macrophages expressed this chemokine (<xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1A</xref>). However, CCL17 expression was not detected in the aorta of wild-type mice without atherosclerotic plaques (<xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1A</xref>). Another ligand CCL22 was modestly expressed in atherosclerotic lesions and partially colocalized with lesional MOMA-2<sup>+</sup> macrophages in <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, while its expression was not detected in the aorta of wild-type mice (<xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1B</xref>).</p><p>Together, these findings suggest that Tregs may migrate to peripheral LNs and atherosclerotic lesions partly via the CCL17/CCL22–CCR4 axes under hypercholesterolemia.</p></sec><sec id="s2-2"><title>CCR4 deficiency accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype</title><p>To investigate the effect of CCR4 deficiency on the development of early atherosclerosis, we analyzed the atherosclerotic lesions of 18-week-old <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice fed a standard chow diet. <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice developed normally without any spontaneous inflammatory disease. Notably, compared with <italic>Apoe</italic><sup>-/-</sup> mice, <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice exhibited a significant increase in atherosclerotic lesion size in the aortic sinus (aortic sinus mean plaque area: control <italic>Apoe</italic><sup>-/-</sup> mice: 1.46±0.50×10<sup>5</sup> μm<sup>2</sup> versus <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>: 2.04±0.82 × 10<sup>5</sup> μm<sup>2</sup>, p&lt;0.05; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). In parallel with the cross-sectional studies, we performed en face analysis of thoracoabdominal aortas, revealing no significant difference in aortic plaque burden between the two groups (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). There were no significant differences in body weight or plasma lipid profile between the two groups (<xref ref-type="table" rid="table1">Table 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>C-C chemokine receptor 4 (CCR4) deficiency accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype.</title><p>(<bold>A</bold>) Representative photomicrographs of Oil Red O staining and quantitative analysis of atherosclerotic lesion area at five different levels and the average area in the aortic sinus of 18-week-old apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) mice (n=24) or CCR4-deficient mice on an <italic>Apoe</italic><sup>-/-</sup> background (<italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>; n=23). (<bold>B</bold>) Representative photomicrographs of Oil Red O staining and quantitative analysis of atherosclerotic lesion area in the aorta of 18-week-old <italic>Apoe</italic><sup>-/-</sup> (n=15) or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (n=15). (<bold>C–E</bold>) Representative sections and quantitative analyses of MOMA-2<sup>+</sup> macrophages (<bold>C</bold>), CD4<sup>+</sup> T cells (<bold>D</bold>), and collagen (<bold>E</bold>) in the aortic sinus. Arrowheads indicate the CD4<sup>+</sup> T cells. n=10 per group. (<bold>F</bold>) mRNA expression of pro- or anti-inflammatory cytokines and helper T cell-associated transcription factors in aorta. The expression levels of the target genes were normalized so that the mean values in <italic>Apoe</italic><sup>-/-</sup> mice were set to 1. n=8–10 per group. Eighteen-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were used for all experiments. Black bars represent 50, 200, or 500 μm as described. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; Mann–Whitney <italic>U</italic>-test: (<bold>A</bold>) and (<bold>F</bold>) <italic>l1b</italic>; two-tailed Student’s <italic>t</italic>-test: (<bold>C–F</bold>) <italic>Il6</italic>, <italic>Tbx21</italic>, and <italic>Rorc</italic>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig1">Figure 1</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig1-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Body weight and plasma lipid profile in 18-week-old mice.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"><italic>Apoe</italic><sup>-/-</sup></th><th align="left" valign="bottom"><italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup></th></tr></thead><tbody><tr><td align="left" valign="bottom">Body weight (g)</td><td align="left" valign="bottom">31.76±1.94 (n=27)</td><td align="left" valign="bottom">31.69±2.24 (n=27)</td></tr><tr><td align="left" valign="bottom">Total cholesterol (mg/dL)</td><td align="left" valign="bottom">526.5±146.3 (n=10)</td><td align="left" valign="bottom">520.4±150.6 (n=10)</td></tr><tr><td align="left" valign="bottom">High-density lipoprotein-cholesterol (mg/dL)</td><td align="left" valign="bottom">24.90±6.49 (n=10)</td><td align="left" valign="bottom">19.80±5.87 (n=10)</td></tr><tr><td align="left" valign="bottom">Triglycerides (mg/dL)</td><td align="left" valign="bottom">89.70±21.07 (n=10)</td><td align="left" valign="bottom">86.40±39.58 (n=10)</td></tr></tbody></table></table-wrap><p>To determine the effect of CCR4 deficiency on plaque components, we performed immunohistochemical studies of atherosclerotic lesions in the aortic sinus. Notably, compared with those of <italic>Apoe</italic><sup>-/-</sup> mice, the atherosclerotic lesions of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice showed a 20% increase in macrophage accumulation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) and a marked 42% increase in CD4<sup>+</sup> T cell infiltration (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In addition, we performed immunohistochemical analysis of Foxp3<sup>+</sup> Tregs in atherosclerotic lesions using an anti-Foxp3 antibody. However, few Foxp3<sup>+</sup> Tregs were found within the plaques of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (data not shown). The proportion of collagen in the aortic sinus plaques of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice was significantly lower than that in the aortic sinus plaques of <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). These findings on atherosclerotic plaque size and components collectively suggest that CCR4 plays a role in preventing the development of early atherosclerotic lesions and inducing a less inflammatory plaque phenotype. To further evaluate aortic immunoinflammatory responses, we analyzed the mRNA expression of pro- and anti-inflammatory cytokines and transcription factors specific for Tregs or helper T cell subsets in atherosclerotic aorta by quantitative reverse transcription PCR. The mRNA expression of proinflammatory cytokines (<italic>Il1b</italic> and <italic>Il6</italic>), Th1-related <italic>Tbx21</italic>, and Th17-related <italic>Rorc</italic> was markedly upregulated in the aorta of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, indicating augmented proatherogenic immune responses in the atherosclerotic aorta (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The mRNA expression of the Treg-specific transcription factor <italic>Foxp3</italic> was undetectable.</p><p>Collectively, these data suggest that CCR4 deficiency promotes the accumulation of inflammatory cells and proinflammatory immune responses in the aorta, leading to augmented development of early atherosclerotic lesions in the aortic root.</p></sec><sec id="s2-3"><title>CCR4 deficiency augments Teff immune responses in peripheral lymphoid tissues</title><p>We examined the mechanisms by which CCR4 deficiency accelerates early atherosclerosis by focusing on changes in systemic T cell responses, including those involving CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs, in peripheral lymphoid tissues. The frequencies of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells were significantly higher in the spleen of 8- or 18-week-old <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in those of age-matched <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). A similar tendency was observed for the peripheral LNs of these mice, although there was no difference in the frequency of CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells between 8-week-old <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). The absolute numbers of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells were significantly higher in the peripheral LNs of 8- or 18-week-old <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than those of age-matched <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). The absolute number of CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells was also higher in the spleen of 18-week-old <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than that of age-matched <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Similar results were obtained for normocholesterolemic wild-type mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>), suggesting that the expansion of Tregs and effector memory T cells in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice is independent of hypercholesterolemia. We evaluated the proliferative capacity of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs by analyzing Ki-67 expression using flow cytometry and found that the proportions of Ki-67-positive Tregs and non-Tregs were markedly higher in the peripheral LNs and spleen of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in those of <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). To determine the effect of CCR4 deficiency on T cell development in the thymus, we performed flow cytometric analysis of thymocytes from 4-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice and found no difference in the development of thymic T cells between the two groups (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). In line with a previous report in normocholesterolemic mice (<xref ref-type="bibr" rid="bib18">Lee et al., 2005</xref>), there was no difference in the frequency of thymic CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs between the two groups (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). These data indicate that the increased numbers of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs in peripheral LNs are due to their enhanced proliferative capacity but not to their promoted development in the thymus. We also analyzed other immune cells in the spleen of <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice by flow cytometry and found no major differences in the proportions or activation-associated molecule expression between the two groups, except for CD86 expression on DCs which was upregulated in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>C-C chemokine receptor 4 (CCR4) deficiency augments effector T cell immune responses in peripheral lymphoid tissues.</title><p>(<bold>A, B</bold>) Representative flow cytometric analysis of CD4<sup>+</sup> forkhead box P3 (Foxp3)<sup>+</sup> regulatory T cells (Tregs) (<bold>A</bold>) and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells (<bold>B</bold>) in the spleen of 8-week-old apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) mice or CCR4-deficient mice on an <italic>Apoe</italic><sup>-/-</sup> background (<italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>). The graphs represent the total numbers and proportions of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (<bold>A</bold>) and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells (<bold>B</bold>) in the peripheral lymph nodes (LNs) and spleen of 8- or 18- week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. n=9–10 per group. (<bold>C, D</bold>) The graphs represent the proportions of Ki-67-positive cells among CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (<bold>C</bold>) and CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs (<bold>D</bold>) in the peripheral LNs and spleen of 8-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, as assessed by flow cytometry. n=13 per group. (<bold>E</bold>) Expression levels of activation-associated molecules cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and CD103 were analyzed by gating on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in the peripheral LNs of 8- or 18-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. n=9–10 per group. (<bold>F</bold>) mRNA expression of Treg-associated markers in splenic Tregs from 8-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. n=8 per group. (<bold>G</bold>) Expression levels of activation-associated molecules CTLA-4 and CD103 were analyzed by gating on CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs in the peripheral LNs of 8- or 18-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. n=9–10 per group. (<bold>H</bold>) mRNA expression of activation-associated molecules in splenic non-Tregs from 8-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. n=8 per group. The expression levels of the target genes were normalized so that the mean values in <italic>Apoe</italic><sup>-/-</sup> mice were set to 1 (<bold>F, H</bold>). Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; Mann–Whitney <italic>U</italic>-test: (<bold>A</bold>) second (8w) from the left, (<bold>B</bold>) second (8w) and third (8w) from the left, (<bold>C</bold>, left, and <bold>H</bold>) <italic>Cd44</italic> and <italic>Cd103</italic>; two-tailed Student’s <italic>t</italic>-test: (<bold>A</bold>) first, second (18w), and third from the left, (<bold>B</bold>) first, second (18w), third (18w), and fourth from the left, (<bold>C</bold>, right, <bold>D</bold>, <bold>E</bold>, <bold>G</bold>, and <bold>H</bold>) <italic>Ctla4</italic>. MFI, mean fluorescence intensity.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig2">Figure 2</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>CCR4 deficiency expands peripheral Tregs and effector memory T cells in the peripheral lymphoid tissues of normocholesterolemic mice.</title><p>Representative flow cytometric analysis of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (<bold>A</bold>) and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells (<bold>B</bold>) in the peripheral lymph nodes (LNs) and spleen of 8-week-old wild-type or <italic>Ccr4</italic><sup>-/-</sup> mice. The graphs represent the total numbers and proportions of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (<bold>A</bold>) and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells (<bold>B</bold>) in the peripheral LNs and spleen. n=5–6 per group. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; Mann–Whitney <italic>U</italic>-test: (<bold>B</bold>) second and third from the left; two-tailed Student’s <italic>t</italic>-test: (<bold>A, B</bold>) fourth from the left.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>CCR4 deficiency does not affect T cell development in the thymus.</title><p>Lymphoid cells from the thymus of 4-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were prepared. (<bold>A</bold>) Representative flow cytometric analysis of CD4 and CD8 expression in thymocytes. The graphs represent the numbers and proportions of CD4/CD8 double-positive (CD4<sup>+</sup>CD8<sup>+</sup>), CD4 single-positive (CD4<sup>+</sup>), and CD8 single-positive (CD8<sup>+</sup>) T cells among thymocytes. (<bold>B</bold>) Representative flow cytometric analysis of Foxp3 expression among the TCR-β<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> population. The graph represents the proportion of Foxp3<sup>+</sup> Tregs among the TCR-β<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> population. n=6 per group. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig2-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>CCR4 deficiency has a minor effect on the proportions of other immune cells in the spleen.</title><p>Proportions of splenic CD8<sup>+</sup> T cells, B220<sup>+</sup> B cells, CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophils, CD11b<sup>+</sup>Ly6C<sup>high</sup> monocytes, NK cells, NKT cells, and CD11c<sup>+</sup>MHC-II<sup>+</sup> DCs, and the expression of CD80 and CD86 on CD11c<sup>+</sup>MHC-II<sup>+</sup> DCs in 8-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were determined by flow cytometry. n=5 per group. Data are representative of two independent experiments. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. **p&lt;0.01; two-tailed Student’s <italic>t</italic>-test. MFI, mean fluorescence intensity.</p><p><supplementary-material id="fig2s3sdata1"><label>Figure 2—figure supplement 3—source data 1.</label><caption><title>Raw numerical valuse for <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig2-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>The effect of CCR4 deficiency on the expression of various chemokine receptors in splenic Tregs and non-Tregs.</title><p>mRNA expression of chemokine receptors in splenic Tregs (<bold>A</bold>) and non-Tregs (<bold>B</bold>) from 8-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. The expression levels of the target genes were normalized so that the mean values in <italic>Apoe</italic><sup>-/-</sup> mice were set to 1. n=8 per group. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. **p&lt;0.01; Mann–Whitney <italic>U</italic>-test: (<bold>B</bold>) top first and third from the left and bottom third from the left; two-tailed Student’s <italic>t</italic>-test: (<bold>B</bold>) bottom first and second from the left. ND, not detected.</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig2-figsupp4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig2-figsupp4-v1.tif"/></fig></fig-group><p>To determine the activation and function of CCR4-deficient CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs, we investigated the expression of their activation- and function-associated molecules in the peripheral LNs of 8- or 18-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice by flow cytometry. Notably, CCR4 deficiency had no major effect on the expression of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) or CD103 in CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). We also analyzed the mRNA expression of <italic>Ccr4</italic>, activation- or function-associated molecules (<italic>Foxp3</italic>, <italic>Ctla4</italic>, <italic>Cd103</italic>, <italic>Tnfrsf18</italic>, <italic>Il10</italic>, and <italic>Tgfb</italic>), and major chemokine receptors (<italic>Ccr5</italic>, <italic>Ccr6</italic>, <italic>Ccr7</italic>, and <italic>Ccr8</italic>) in splenic Tregs by quantitative reverse transcription PCR. The <italic>Ccr4</italic> mRNA expression in Tregs from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice was less than the detectable levels (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>). In line with the data on peripheral LNs, there were no significant differences in the mRNA expression of these molecules between the two groups (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>).</p><p>In contrast to the results on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs, the expression of the activation marker CTLA-4 in peripheral LN CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs was higher in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in <italic>Apoe</italic><sup>-/-</sup> mice, although the expression of another activation marker CD103 was not altered by CCR4 deficiency (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). We analyzed the mRNA expression of <italic>Ccr4</italic>, activation-associated molecules (<italic>Ctla4</italic>, <italic>Cd44</italic>, <italic>Cd69</italic>, and <italic>Cd103</italic>), and representative chemokine receptors (<italic>Ccr1</italic>, <italic>Ccr5</italic>, <italic>Ccr6</italic>, <italic>Ccr7</italic>, <italic>Ccr8</italic>, <italic>Cxcr3</italic>, and <italic>Cx3cr1</italic>) in splenic non-Tregs by quantitative reverse transcription PCR. The <italic>Ccr4</italic> mRNA expression in non-Tregs from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice was less than the detectable levels (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>). We found a marked increase in the mRNA expression of activation-associated molecules (<italic>Ctla4</italic>, <italic>Cd44</italic>, and <italic>Cd103</italic>) in splenic non-Tregs from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). We also observed upregulated mRNA expression of various chemokine receptors, including Th1-related <italic>Ccr1</italic>, <italic>Cxcr3</italic>, and <italic>Cx3cr1</italic>, Th2-related <italic>Ccr8</italic>, and Th17-related <italic>Ccr6</italic> in splenic non-Tregs from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>), indicating that CCR4 deficiency may promote the activation and expansion of helper T cells and facilitate their migration to atherosclerotic lesions. There were no significant differences in the mRNA expression of other chemokine receptors (<italic>Ccr5</italic> and <italic>Ccr7</italic>) in splenic non-Tregs between the two groups (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>).</p><p>Considering the accelerated early atherosclerosis observed in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, these results indicate that augmented Teff immune responses may affect atherosclerosis more strongly than the increase in Tregs in peripheral lymphoid tissues.</p></sec><sec id="s2-4"><title>CCR4 deficiency promotes proinflammatory CD4<sup>+</sup> T cell immune responses in peripheral lymphoid tissues</title><p>To determine whether CCR4 deficiency affects CD4<sup>+</sup> T cell immune responses and polarization, we examined cytokine secretion from CD4<sup>+</sup> T cells by intracellular cytokine staining. The fraction of IFN-γ-producing Th1 cells in the peripheral LNs was significantly higher in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in <italic>Apoe</italic><sup>-/-</sup> mice, while there were no differences in the fractions of other CD4<sup>+</sup> T cell subsets including interleukin (IL)-4-producing Th2 cells, IL-10-producing CD4<sup>+</sup> T cells, and IL-17-producing Th17 cells between the two groups (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In line with this, the fraction of splenic Th1 cells was higher in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in <italic>Apoe</italic><sup>-/-</sup> mice, although the proportion of IL-17-producing Th17 cells was also higher in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>C-C chemokine receptor 4 (CCR4) deficiency promotes proinflammatory CD4<sup>+</sup> T cell immune responses in peripheral lymphoid tissues.</title><p>(<bold>A, B</bold>) The graphs represent the frequencies of interferon (IFN)-γ<sup>+</sup>, interleukin (IL)–4<sup>+</sup>, IL-10<sup>+</sup>, and IL-17<sup>+</sup> CD4<sup>+</sup> T cells in the peripheral lymph nodes (LNs) (<bold>A</bold>) and spleen (<bold>B</bold>) of 8-week-old apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) mice or CCR4-deficient mice on an <italic>Apoe</italic><sup>-/-</sup> background (<italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>). n=10–11 per group. (<bold>C, D</bold>) Purified splenic CD4<sup>+</sup> T cells from 8-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were stimulated with plate-bound anti-CD3 and soluble anti-CD28 antibodies in vitro. The levels of various cytokines and chemokines in pooled cell supernatants from eight mice in each group were determined semiquantitatively by a cytokine array kit (<bold>C</bold>). Data are representative of two independent experiments. Cytokine concentrations in the cell supernatants were measured by ELISA (<bold>D</bold>). n=8 per group. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; Mann–Whitney <italic>U</italic>-test: (<bold>A</bold>, <bold>B</bold>) first from the left, and<bold> (D</bold>) second from the left; two-tailed Student’s <italic>t</italic>-test: (<bold>B</bold>) fourth from the left and (<bold>D</bold>) first, third, and fourth from the left.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig3">Figure 3</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig3-v1.tif"/></fig><p>We semiquantitatively analyzed the production of various cytokines or chemokines by splenic CD4<sup>+</sup> T cells stimulated with plate-bound anti-CD3 and anti-CD28 antibodies using a cytokine array kit. Compared with those from <italic>Apoe</italic><sup>-/-</sup> mice, splenic CD4<sup>+</sup> T cells from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice secreted more Th1-related cytokine IFN-γ, Th2-related cytokine IL-13, Th17-related cytokine IL-17, and various inflammation-related cytokines and chemokines (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). ELISA analysis confirmed that the IFN-γ and IL-17 levels in the cell supernatants of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were much higher than those in the cell supernatants of <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Although the cytokine levels of Th2-related cytokine IL-4 and Treg-related anti-inflammatory cytokine IL-10 were below the detectable levels by cytokine array analysis, ELISA analysis revealed higher IL-4 and IL-10 production in splenic CD4<sup>+</sup> T cells from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in those from <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), which may be compensatory immune responses to the proinflammatory T cell responses caused by CCR4 deficiency.</p></sec><sec id="s2-5"><title>CCR4 deficiency promotes Th1 cell responses in para-aortic LNs and atherosclerotic aorta</title><p>Next, we investigated the mechanisms by which CCR4 deficiency accelerates early atherosclerosis by focusing on local immune responses in para-aortic LNs and atherosclerotic aorta. Consistent with the peripheral LN data, the frequency and number of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs were significantly higher in the para-aortic LNs of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in those of <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The number of CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells was significantly higher in the para-aortic LNs of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in those of <italic>Apoe</italic><sup>-/-</sup> mice, while their frequency did not differ between the two groups (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>C-C chemokine receptor 4 (CCR4) deficiency promotes T helper type 1 (Th1) cell responses in para-aortic lymph nodes (LNs) and atherosclerotic aorta.</title><p>(<bold>A, B</bold>) Representative flow cytometric analysis of CD4<sup>+</sup> forkhead box P3 (Foxp3)<sup>+</sup> regulatory T cells (Tregs) (<bold>A</bold>) and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells (<bold>B</bold>) in para-aortic LNs. The graphs represent the total numbers and proportions of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (<bold>A</bold>) and CD4<sup>+</sup>CD44<sup>high</sup>CD62L<sup>low</sup> effector memory T cells (<bold>B</bold>) in para-aortic LNs. n=9–10 per group. (<bold>C, D</bold>) mRNA expression of Treg-associated markers in Tregs (<bold>C</bold>) and mRNA expression of activation or helper T cell-associated molecules in non-Tregs (<bold>D</bold>) in para-aortic LNs. The expression levels of the target genes were normalized so that the mean values in apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) mice were set to 1. Tregs or non-Tregs purified from pooled para-aortic LNs of 9–10 mice were analyzed as a sample. n=4 per group. (<bold>E</bold>) The graphs represent the frequencies of interferon (IFN)-γ<sup>+</sup>, interleukin (IL)–4<sup>+</sup>, IL-10<sup>+</sup>, and IL-17<sup>+</sup> CD4<sup>+</sup> T cells in para-aortic LNs. n=12 per group. (<bold>F–H</bold>) Representative flow cytometric analysis of T-box expressed in T cells (T-bet) (<bold>F</bold>), GATA3 (<bold>G</bold>), and retinoic acid-related orphan receptor gamma t (RORγt) (<bold>H</bold>) expression in aortic CD3<sup>+</sup>CD4<sup>+</sup>CD45<sup>+</sup> T cells. The graphs represent the frequencies of T-bet<sup>+</sup> (<bold>F</bold>), GATA3<sup>+</sup> (<bold>G</bold>), and RORγt<sup>+</sup> (<bold>H</bold>) cells among aortic CD3<sup>+</sup>CD4<sup>+</sup>CD45<sup>+</sup> T cells. n=9 per group. (<bold>I</bold>) Representative flow cytometric analysis of Foxp3 expression in aortic CD3<sup>+</sup>CD4<sup>+</sup>CD45<sup>+</sup> T cells. The graph represents the frequency of Foxp3<sup>+</sup> Tregs among aortic CD3<sup>+</sup>CD4<sup>+</sup>CD45<sup>+</sup> T cells. n=9 per group. (<bold>J</bold>) The graph represents the ratio of CD4<sup>+</sup>T-bet<sup>+</sup> Th1 cells to CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (Th1 cell/Treg ratio). n=9 per group. Pooled aortic lymphoid cells from two mice were analyzed as a sample. Eighteen-week-old <italic>Apoe</italic><sup>-/-</sup> or CCR4-deficient mice on an <italic>Apoe</italic><sup>-/-</sup> background (<italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>) were used for all experiments. Data points represent individual animals (<bold>A</bold>, <bold>B</bold>, and<bold> E</bold>) or individual pooled samples (<bold>C, D, F–J</bold>). Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; Mann–Whitney <italic>U</italic>-test: (<bold>D</bold>) <italic>Cd103</italic> and (<bold>J</bold>); two-tailed Student’s <italic>t</italic>-test: (<bold>A, B</bold>, <bold>D</bold>) <italic>Tbx21</italic>, (<bold>E</bold>, <bold>F</bold>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig4">Figure 4</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>CCR4 deficiency does not affect the expression of activation- or function-associated molecules in Tregs in para-aortic lymph nodes (LNs).</title><p>Expression levels of CTLA-4, CD103, and PD-1 were analyzed by gating on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in the para-aortic LNs of 18-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. n=9–10 per group. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. MFI, mean fluorescence intensity.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The effect of CCR4 deficiency on the expression of various chemokine receptors in Tregs and non-Tregs in para-aortic lymph nodes (LNs).</title><p>mRNA expression of chemokine receptors in Tregs (<bold>A</bold>) and non-Tregs (<bold>B</bold>) in the para-aortic LNs of 18-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. The expression levels of the target genes were normalized so that the mean values in <italic>Apoe</italic><sup>-/-</sup> mice were set to 1. Tregs or non-Tregs purified from pooled para-aortic LNs of 9–10 mice were analyzed as a sample. n=4 per group. Data points represent individual pooled samples. Horizontal bars represent means. Error bars indicate s.d.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig4-figsupp2-v1.tif"/></fig></fig-group><p>In line with the data on peripheral lymphoid tissues, there were no significant differences in the expression of activation- or function-associated molecules or chemokine receptors in para-aortic LN Tregs between the two groups (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2A</xref>). Notably, the expression of <italic>Cd103</italic> and Th1-related <italic>Tbx21</italic> was upregulated in para-aortic LN non-Tregs from <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, while the expression of other activation- or helper T cell-associated molecules or chemokine receptors was unaltered (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Flow cytometric analysis of helper T cell subsets in para-aortic LNs revealed that the fractions of IFN-γ-producing Th1 cells, IL-4-producing Th2 cells, and IL-17-producing Th17 cells were significantly higher in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in <italic>Apoe</italic><sup>-/-</sup> mice, suggesting augmented proinflammatory CD4<sup>+</sup> T cell immune responses by CCR4 deficiency (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>We explored the infiltration of T-box expressed in T cells (T-bet)-expressing Th1 cells, GATA3-expressing Th2 cells, and retinoic acid-related orphan receptor gamma t (RORγt)-expressing Th17 cells in atherosclerotic aorta by flow cytometry. Strikingly, the frequency of aortic T-bet-expressing Th1 cells was markedly higher in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice than in <italic>Apoe</italic><sup>-/-</sup> mice, while the proportions of Th2 and Th17 subsets did not differ between the two groups (<xref ref-type="fig" rid="fig4">Figure 4F–H</xref>). We next analyzed the accumulation of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in the atherosclerotic aorta by flow cytometry and found no difference in the proportion of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs between the two groups (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Importantly, we found a marked increase in the ratio of T-bet-expressing Th1 cells to CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs (Th1 cell/Treg ratio) in the atherosclerotic aorta of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4J</xref>), indicating Th1-skewed immune responses in the atherosclerotic lesions of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice.</p><p>Collectively, these results suggest that CCR4 deficiency promotes the selective accumulation of proatherogenic Th1 cells in atherosclerotic aorta and the accumulation of various helper T cell subsets including Th1 cells in para-aortic LNs and shifts the Th1 cell/Treg balance toward Th1 cell responses in atherosclerotic aorta, leading to exacerbated aortic inflammation and early atherosclerosis.</p></sec><sec id="s2-6"><title>CCR4 expression on Tregs regulates Th1 cell responses and may mediate Treg migration to the atherosclerotic aorta</title><p>Given that CCR4 plays a crucial role in attenuating immunoinflammatory responses in autoimmune or allergic disease via the modulation of Treg function (<xref ref-type="bibr" rid="bib42">Yuan et al., 2007</xref>; <xref ref-type="bibr" rid="bib8">Faustino et al., 2013</xref>), we speculated that despite the expansion and unaltered expression of activation- or function-associated molecules in Tregs, these cells might be dysfunctional. To determine whether CCR4 deficiency affects the suppressive function of Tregs in hypercholesterolemia, we performed an in vitro suppression assay. Interestingly, CCR4 deficiency significantly impaired the suppressive function of Tregs isolated from hypercholesterolemic mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), indicating that CCR4 expression on Tregs may be important for the regulation of proinflammatory immune responses and the development of early atherosclerosis.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>C-C chemokine receptor 4 (CCR4) expression on regulatory T cells (Tregs) regulates T helper type 1 cell responses and mediates Treg migration to the aorta.</title><p>(<bold>A</bold>) The suppressive function of Tregs was assessed by evaluating the proliferation of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled conventional T cells (Tconv) cocultured with Tregs from apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) mice or CCR4-deficient mice on an <italic>Apoe</italic><sup>-/-</sup> background (<italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>). Data are presented as the results of triplicate wells and are representative of two independent experiments. Data are expressed as the mean ± s.d. (<bold>B, C</bold>) CD80 and CD86 expression in live splenic dendritic cells (DCs) after 2 days of coculture with Tconv from <italic>Apoe</italic><sup>-/-</sup> mice, or a mixture of Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice and Tconv from <italic>Apoe</italic><sup>-/-</sup> mice in the presence of an anti-CD3 antibody. Data points represent the results of quintuplicate wells. Data are representative of two independent experiments. (<bold>B, D</bold>) Tconv from <italic>Apoe</italic><sup>-/-</sup> mice and DCs were cocultured with or without Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice in the presence of an anti-CD3 antibody. Interferon (IFN)-γ concentrations in cell supernatants were measured by ELISA. Data points represent the results of sextuplicate wells. (<bold>E</bold>) Eighteen-week-old <italic>Apoe</italic><sup>-/-</sup> mice fed a high-cholesterol diet for 10 weeks received transfer of Tregs from <italic>Apoe</italic><sup>-/-</sup>Kaede-Tg or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>Kaede-Tg mice, and the accumulation of Kaede<sup>+</sup> Tregs in the peripheral lymphoid tissues and aorta was analyzed by flow cytometry 20 hours later. (<bold>F–I</bold>) Representative flow cytometric analysis and the proportions of Kaede<sup>+</sup> Tregs among CD4<sup>+</sup> T cells in the peripheral lymph nodes (LNs) (<bold>F</bold>), spleen (<bold>G</bold>), para-aortic LNs (<bold>H</bold>), and aorta (<bold>I</bold>) of <italic>Apoe</italic><sup>-/-</sup> mice that received <italic>Apoe</italic><sup>-/-</sup>Kaede<sup>+</sup> Tregs or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>Kaede<sup>+</sup> Tregs. n=9–10 per group (<bold>F–H</bold>). Pooled aortic lymphoid cells from five mice in each group were used for analysis. The results are presented as the mean ±s.d. of three independent experiments (<bold>I</bold>). Data points represent individual animals (<bold>F–H</bold>) or individual pooled samples (<bold>I</bold>). Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; one-way ANOVA followed by Tukey’s multiple-comparisons test: (<bold>C, D</bold>); two-way ANOVA followed by Tukey’s multiple-comparisons test: (<bold>A</bold>). p=0.09; one-sample <italic>t</italic>-test: (<bold>I</bold>). MFI, mean fluorescence intensity.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig5">Figure 5</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig5-v1.tif"/></fig><p>Interaction with DCs is well-known as one of the core suppressive mechanisms by which Tregs control excessive immune responses. A previous report demonstrated that the cell–cell contacts between Tregs and CCL22-deficient DCs are impaired (<xref ref-type="bibr" rid="bib24">Rapp et al., 2019</xref>). Tregs limit the CD80/CD86–CD28-dependent activation of T cells through CTLA-4-dependent downregulation of CD80 and CD86 expression on DCs (<xref ref-type="bibr" rid="bib27">Sakaguchi et al., 2020</xref>), which may contribute to the reduction in atherosclerosis (<xref ref-type="bibr" rid="bib19">Matsumoto et al., 2016</xref>). Therefore, we examined the interactions between CCR4-intact or CCR4-deficient Tregs and DCs by a coculture experiment (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). As expected, the upregulation of CD80 and CD86 expression on DCs mediated by conventional T cells was markedly suppressed by coculture with Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Notably, the suppressive effect of CCR4-deficient Tregs was significantly attenuated compared with that of CCR4-intact Tregs (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). To assess the involvement of CCR4 expression on Tregs in regulating the production of proatherogenic IFN-γ by conventional T cells, we stimulated conventional T cells with an anti-CD3 antibody and DCs in the presence or absence of CCR4-intact or CCR4-deficient Tregs and analyzed IFN-γ production by ELISA (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). IFN-γ production by conventional T cells was markedly suppressed by coculture with CCR4-intact Tregs, while it was not significantly affected by coculture with CCR4-deficient Tregs (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Importantly, there was a marked difference in the ability to suppress the production of IFN-γ from conventional T cells between CCR4-intact Tregs and CCR4-deficient Tregs (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). These results suggest that the augmented Th1 cell responses in the peripheral lymphoid tissues of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice are partly due to impaired Treg-dependent regulation of DC function.</p><p>As described above, CD4<sup>+</sup>Foxp3<sup>+</sup> Treg accumulation in the atherosclerotic aorta of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice was not altered despite the marked expansion of CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in peripheral lymphoid tissues. Based on these findings and previous reports showing the impaired migratory capacity of CCR4-deficient Tregs to inflammatory tissues (<xref ref-type="bibr" rid="bib42">Yuan et al., 2007</xref>; <xref ref-type="bibr" rid="bib8">Faustino et al., 2013</xref>), we hypothesized that CCR4-deficient Tregs might have less capacity to migrate to atherosclerotic lesions. To address this issue, we performed a Treg transfer experiment using <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice on a Kaede-Tg background (<xref ref-type="bibr" rid="bib36">Tomura et al., 2008</xref>), which provided us with the opportunity to faithfully track transferred Tregs by monitoring the fluorescent Kaede protein (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). There was no difference in the migratory capacity of CCR4-intact or CCR4-deficient Kaede-expressing Tregs to the peripheral LNs, spleen, or para-aortic LNs of recipient <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5F–H</xref>). To promote the accumulation of T cells in atherosclerotic aorta, we fed recipient <italic>Apoe</italic><sup>-/-</sup> mice with a high-cholesterol diet and analyzed the migration of transferred Tregs in the aorta. Interestingly, we found a trend toward reduction in the proportion of CCR4-deficient Kaede-expressing Tregs in the aorta of recipient <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5I</xref>), suggesting that CCR4-deficient Tregs may have a reduced ability to migrate to the atherosclerotic aorta, but not to the peripheral lymphoid tissues, under hypercholesterolemia.</p><p>Taken together, these data demonstrate that CCR4 expression on Tregs plays a critical role in regulating Th1 cell responses in lymphoid tissues and may mediate Treg migration to the atherosclerotic aorta under hypercholesterolemia, which may cooperatively contribute to the reduction in early atherosclerosis by efficiently mitigating aortic inflammatory immune responses.</p></sec><sec id="s2-7"><title>CCR4 expression on Tregs is critical for limiting aortic inflammation and the development of atherosclerosis</title><p>To provide direct evidence for the critical role of CCR4 expression in Tregs in reducing early atherosclerosis, we injected <italic>Apoe</italic><sup>-/-</sup> mice with saline or Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice and analyzed the aortic root atherosclerotic lesions of recipient <italic>Apoe</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Although there were no significant differences in the aortic sinus mean plaque area among the three groups (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), detailed analysis of the aortic root plaques at five different levels revealed significantly greater lesions in <italic>Apoe</italic><sup>-/-</sup> mice that were administered CCR4-deficient Tregs than in <italic>Apoe</italic><sup>-/-</sup> mice that were administered CCR4-intact Tregs (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), suggesting that the impaired CCR4-deficient Treg function is involved in the acceleration of atherosclerosis in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. There were no significant differences in body weight or plasma lipid profile among the three groups (<xref ref-type="table" rid="table2">Table 2</xref>). We further aimed to confirm these findings by performing an additional experiment in which recipient <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were administered Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice or PBS and atherosclerotic lesions were analyzed (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>). There were no major differences in body weight or plasma lipid profile among the three groups (<xref ref-type="table" rid="table3">Table 3</xref>). The anti-atherogenic effect of CCR4 expression in Tregs was not observed in these mice (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>). This could possibly be explained by the dysfunction of Tregs under the enhanced inflammatory conditions in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>C-C chemokine receptor 4 (CCR4) expression on regulatory T cells (Tregs) is critical for limiting aortic inflammation and the development of early atherosclerosis.</title><p>(<bold>A</bold>) Tregs purified from the peripheral lymph nodes (LNs) and spleen of apolipoprotein E-deficient (<italic>Apoe</italic><sup>-/-</sup>) mice or CCR4-deficient mice on an <italic>Apoe</italic><sup>-/-</sup> background (<italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup>) were intravenously transferred into 12-week-old <italic>Apoe</italic><sup>-/-</sup> mice fed a standard chow diet, and atherosclerotic lesions were analyzed at 16 weeks of age. As a control without cell transfer, 12-week-old <italic>Apoe</italic><sup>-/-</sup> mice were intravenously injected with saline and atherosclerotic lesions were analyzed at 16 weeks of age. (<bold>B</bold>) Representative photomicrographs of Oil Red O staining and quantitative analysis of atherosclerotic lesion area at five different levels and maximal lesions in the aortic sinus of <italic>Apoe</italic><sup>-/-</sup> mice injected with saline (n=19), <italic>Apoe</italic><sup>-/-</sup> Tregs (n=17), or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs (n=20). (<bold>C–E</bold>) Representative sections and quantitative analyses of MOMA-2<sup>+</sup> macrophages (<bold>C</bold>), CD4<sup>+</sup> T cells (<bold>D</bold>), and collagen (<bold>E</bold>) in the aortic sinus of <italic>Apoe</italic><sup>-/-</sup> mice injected with saline, <italic>Apoe</italic><sup>-/-</sup> Tregs, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs. Arrowheads indicate the CD4<sup>+</sup> T cells. n=10 per group. Black bars represent 50, 200, or 500 μm as described. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. *p&lt;0.05, **p&lt;0.01; one-way ANOVA followed by Tukey’s multiple-comparisons test.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig6">Figure 6</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>No significant difference in the mean atherosclerotic lesion area in the aortic sinus was observed among <italic>Apoe</italic><sup>-/-</sup> mice injected with saline, <italic>Apoe</italic><sup>-/-</sup> Tregs, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs.</title><p>Quantitative analysis of the mean atherosclerotic lesion area in the aortic sinus of <italic>Apoe</italic><sup>-/-</sup> mice injected with saline (n=19), <italic>Apoe</italic><sup>-/-</sup> Tregs (n=17), or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs (n=20). Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Transfer of CCR4-intact Tregs does not affect the development of early atherosclerotic lesions in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice.</title><p>(<bold>A</bold>) Tregs purified from the peripheral lymph nodes (LNs) and spleen of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were intravenously transferred into 12-week-old <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice fed a standard chow diet, and atherosclerotic lesions were analyzed at 16 weeks of age. As a control without cell transfer, 12-week-old <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were intravenously injected with saline and atherosclerotic lesions were analyzed at 16 weeks of age. (<bold>B</bold>) Representative photomicrographs of Oil Red O staining and quantitative analysis of atherosclerotic lesion area at five different levels and maximal lesions in the aortic sinus of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice injected with saline (n=19), <italic>Apoe</italic><sup>-/-</sup> Tregs (n=20), or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs (n=20). Black bars represent 500 μm as described. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-fig6-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-fig6-figsupp2-v1.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Body weight and plasma lipid profile in <italic>Apoe</italic><sup>-/-</sup> mice treated with saline, <italic>Apoe</italic><sup>-/-</sup> Tregs, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs.</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Saline</bold></td><td align="left" valign="bottom"><italic><bold>Apoe</bold></italic><sup><bold>-/-</bold></sup><bold>Treg</bold></td><td align="left" valign="bottom"><italic><bold>Ccr4</bold></italic><sup><bold>-/-</bold></sup><italic><bold>Apoe</bold></italic><sup><bold>-/-</bold></sup><bold>Treg</bold></td></tr><tr><td align="left" valign="bottom">Body weight (g)</td><td align="left" valign="bottom">27.82±2.82 (n=18)</td><td align="left" valign="bottom">27.80±2.42 (n=20)</td><td align="left" valign="bottom">27.72±2.59 (n=19)</td></tr><tr><td align="left" valign="bottom">Total cholesterol (mg/dL)</td><td align="left" valign="bottom">505.3±114.0 (n=10)</td><td align="left" valign="bottom">605.5±105.1 (n=10)</td><td align="left" valign="bottom">607.3±76.35 (n=10)</td></tr><tr><td align="left" valign="bottom">High-density lipoprotein-cholesterol (mg/dL)</td><td align="left" valign="bottom">15.00±2.87 (n=10)</td><td align="left" valign="bottom">15.20±3.26 (n=10)</td><td align="left" valign="bottom">13.80±4.83 (n=10)</td></tr><tr><td align="left" valign="bottom">Triglycerides (mg/dL)</td><td align="left" valign="bottom">87.40±36.69 (n=10)</td><td align="left" valign="bottom">92.70±27.15 (n=10)</td><td align="left" valign="bottom">96.60±33.94 (n=10)</td></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Body weight and plasma lipid profile in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice treated with saline, <italic>Apoe</italic><sup>-/-</sup> Tregs, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> Tregs.</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Saline</bold></td><td align="left" valign="bottom"><italic><bold>Apoe</bold></italic><sup><bold>-/-</bold></sup><bold>Treg</bold></td><td align="left" valign="bottom"><italic><bold>Ccr4</bold></italic><sup><bold>-/-</bold></sup><italic><bold>Apoe</bold></italic><sup><bold>-/-</bold></sup><bold>Treg</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Body weight (g)</td><td align="left" valign="bottom">32.44±2.75 (n=12)</td><td align="left" valign="bottom">30.69±3.55 (n=12)</td><td align="left" valign="bottom">32.16±2.12 (n=12)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Total cholesterol (mg/dL)</td><td align="left" valign="bottom">589.1±144.3 (n=10)</td><td align="left" valign="bottom">616.1±105.6 (n=10)</td><td align="left" valign="bottom">526.4±115.9 (n=10)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">High-density lipoprotein-cholesterol (mg/dL)</td><td align="left" valign="bottom">16.30±3.65 (n=10)</td><td align="left" valign="bottom">13.80±3.19 (n=10)</td><td align="left" valign="bottom">12.10±2.96* (n=10)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Triglycerides (mg/dL)</td><td align="left" valign="bottom">83.0±57.56 (n=10)</td><td align="left" valign="bottom">91.60±55.52 (n=10)</td><td align="left" valign="bottom">72.70±13.99 (n=10)</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>To determine the effect of Treg-specific CCR4 deficiency on plaque components, we performed immunohistochemical studies of atherosclerotic lesions in the aortic sinus. Compared with those of saline-injected <italic>Apoe</italic><sup>-/-</sup> mice, the atherosclerotic lesions of <italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-intact Tregs showed markedly reduced accumulation of macrophages (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), whereas there were no differences in intraplaque accumulation of these inflammatory cells between saline-injected <italic>Apoe</italic><sup>-/-</sup> mice and <italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-deficient Tregs (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). Notably, macrophage accumulation in the aortic sinus atherosclerotic lesions was markedly higher in <italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-deficient Tregs than in <italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-intact Tregs (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Collagen content in atherosclerotic lesions was significantly higher in <italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-intact Tregs than in saline-injected <italic>Apoe</italic><sup>-/-</sup> mice, while no difference in collagen was observed between saline-injected <italic>Apoe</italic><sup>-/-</sup> mice and <italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-deficient Tregs (<xref ref-type="fig" rid="fig6">Figure 6E</xref>).</p><p>Overall, we provide evidence that CCR4 protects against early atherosclerosis partly by mediating Treg-dependent induction of a less inflammatory plaque phenotype.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we demonstrated that genetic deletion of CCR4 in hypercholesterolemic <italic>Apoe</italic><sup>-/-</sup> mice accelerates the development of early atherosclerotic lesions in the aortic root that exhibit an inflammatory phenotype, associated with the augmentation of proatherogenic Th1 cell responses in the peripheral lymphoid tissues, para-aortic LNs, and atherosclerotic aorta. Furthermore, T cell-DC coculture and Treg transfer experiments revealed that CCR4 expression on Tregs regulates the development of early atherosclerosis by suppressing Th1 cell responses in lymphoid tissues and possibly by mediating Treg migration to the atherosclerotic aorta. Thus, we identified a novel role for the CCL17/CCL22–CCR4 axes in controlling early atherosclerosis via favorable modulation of the Th1 cell/Treg balance.</p><p>Emerging experimental and clinical data obtained by single-cell RNA sequencing and mass cytometry have clearly shown that CD4<sup>+</sup> or CD8<sup>+</sup> T cells are the dominant populations in human (<xref ref-type="bibr" rid="bib10">Fernandez et al., 2019</xref>) and mouse (<xref ref-type="bibr" rid="bib40">Winkels et al., 2018</xref>) atherosclerotic plaques. Recent experimental and clinical evidence has demonstrated that dysregulation of the balance of proatherogenic Th1 cells and anti-atherogenic Tregs has adverse effects on atherosclerotic disease (<xref ref-type="bibr" rid="bib32">Tanaka et al., 2021</xref>). In the present study, we found that the formation of early atherosclerotic lesions in the aortic root was markedly accelerated by CCR4 deficiency, which was associated with the upregulation of various helper T cell immune responses in peripheral lymphoid tissues and augmented Th1 and Th17 cell-mediated responses in the atherosclerotic aorta. Given the proatherogenic nature of Th1 cells (<xref ref-type="bibr" rid="bib13">Gupta et al., 1997</xref>; <xref ref-type="bibr" rid="bib3">Buono et al., 2005</xref>), our data indicate that augmented Th1 cell responses in peripheral lymphoid tissues, especially in atherosclerotic lesions, substantially contributed to atherosclerotic lesion formation in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. However, we cannot exclude the possibility that augmented immune responses of other helper T cell subsets might also contribute to accelerated atherosclerosis in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice.</p><p>As Th2 cells and some Th17 cells, but not Th1 cells, are known to express CCR4 (<xref ref-type="bibr" rid="bib12">Griffith et al., 2014</xref>), the augmented Th1 cell responses observed in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice do not seem to be direct effects of CCR4 deficiency and may involve other mechanisms. Given our recent report showing the augmented immune responses related to Th1, Th2, and Th17 cells in CD4<sup>+</sup>Foxp3<sup>+</sup> Treg-depleted atherosclerosis-prone mice (<xref ref-type="bibr" rid="bib15">Kasahara et al., 2022</xref>), augmentation of these helper T cell responses may be caused by dysregulated CD4<sup>+</sup>Foxp3<sup>+</sup> Treg responses in our <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. In line with experimental studies in mouse models of inflammatory diseases showing a pivotal role for CCR4 in mediating Treg migration to inflammatory tissues (<xref ref-type="bibr" rid="bib42">Yuan et al., 2007</xref>; <xref ref-type="bibr" rid="bib8">Faustino et al., 2013</xref>), we found that CCR4 expression on Tregs may be critical for their migration to the atherosclerotic aorta, providing a possible mechanism for CCR4-dependent regulation of atherosclerosis. Another interesting finding is that CCR4 deficiency markedly upregulated Th1 cell responses in peripheral lymphoid tissues as well as in atherosclerotic lesions under hypercholesterolemia. This observation may not depend on the activation status of Tregs because there were no major differences in the expression of their activation- and function-associated molecules between <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Despite the lower expression of CD103 in the peripheral LN Tregs of 8-week-old <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, there was no significant difference in its expression levels between 18-week-old <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, indicating that reduced CD103 expression in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice may not be a noteworthy change. T cell-DC coculture experiments clearly demonstrated that CCR4 expression on Tregs is critical for attenuating DC-dependent stimulation of Th1 cell responses by maintaining interactions between Tregs and DCs and Treg suppressive function, which is supported by the findings of a previous report showing a crucial role of the CCL22–CCR4 axis in the contact of Tregs with DCs and regulation of inflammatory responses (<xref ref-type="bibr" rid="bib24">Rapp et al., 2019</xref>). In line with the results of in vitro experiments, we found the upregulation of CD86 expression on DCs in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, which may be derived from the impaired ability of CCR4-deficient Tregs to downregulate CD80 and CD86 expression on DCs. Based on these findings, we propose that CCR4 deficiency in Tregs interrupts their contact with DCs in lymphoid tissues and impairs their suppressive function, leading to augmented Th1 cell responses and accelerated atherosclerosis. We speculate that the increased frequency of Tregs in the peripheral lymphoid tissues of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice may be a compensatory effect in response to augmented Th1 cell-mediated proinflammatory responses due to dysfunctional Tregs.</p><p>T cell costimulatory signals such as the CD28–CD80/CD86 (<xref ref-type="bibr" rid="bib1">Ait-Oufella et al., 2006</xref>) and CD27–CD70 (<xref ref-type="bibr" rid="bib39">Winkels et al., 2017</xref>) pathways protect against atherosclerosis by systemically shifting the Th1 cell/Treg balance toward Treg responses. Several approaches involving treatment with cytokines (<xref ref-type="bibr" rid="bib5">Dinh et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Kasahara et al., 2014</xref>), antibodies (<xref ref-type="bibr" rid="bib28">Sasaki et al., 2009</xref>; <xref ref-type="bibr" rid="bib14">Kasahara et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Steffens et al., 2006</xref>), an active form of vitamin D<sub>3</sub> (<xref ref-type="bibr" rid="bib31">Takeda et al., 2010</xref>), or ultraviolet B irradiation <xref ref-type="bibr" rid="bib29">Sasaki et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Tanaka et al., 2024</xref> have been reported to mitigate atherosclerosis via modulation of the Th1 cell/Treg balance in the peripheral lymphoid tissues and atherosclerotic lesions of atherosclerosis-prone mice. Despite these reports, the mechanisms that regulate the T cell balance in lymphoid tissues, particularly in atherosclerotic lesions, have not been fully elucidated. The chemokine system plays an important role in the differentiation and migration of various subsets of T cells including Tregs and has been shown to be involved in the process of atherosclerosis (<xref ref-type="bibr" rid="bib23">Noels et al., 2019</xref>). We revealed that CCR4 protects against early atherosclerosis by mitigating Th1 cell responses in lymphoid tissues and atherosclerotic lesions and possibly by mediating Treg migration to the aorta. This indicates a previously unrecognized role of the chemokine system in regulating the Th1 cell/Treg balance to limit atherosclerosis.</p><p>We observed the accelerated development of early atherosclerotic lesions in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice fed a standard chow diet. However, previous studies showed that neither hematopoietic nor systemic CCR4 deficiency affected the development of advanced atherosclerotic lesions or Treg frequency in severely hypercholesterolemic mice (<xref ref-type="bibr" rid="bib37">Weber et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Döring et al., 2024</xref>). These findings suggest that the role of CCR4 may vary depending on the stages of atherosclerosis. Given that Treg responses affected by CCR4 deficiency in mice with early atherosclerotic lesions may be different from those in mice with advanced atherosclerotic lesions, we speculate that the difference in Treg responses may be responsible for the inconsistent findings on the role of CCR4 deficiency in atherosclerosis.</p><p>Our data show that interactions between CCR4 and CCL17/CCL22 may promote Treg-skewed responses in lymphoid tissues and atherosclerotic lesions. However, studies in hypercholesterolemic mice demonstrated that genetic deficiency of CCL17 ameliorated atherosclerotic lesion development by promoting Treg accumulation in lymphoid tissues and atherosclerotic lesions independently of the CCL17–CCR4 axis (<xref ref-type="bibr" rid="bib37">Weber et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Döring et al., 2024</xref>). This suggests that CCL17 restrains Treg homeostasis and accelerates atherosclerosis, although the role of the CCL17–CCR4 axis in the regulation of Treg homeostasis and atherosclerosis remains elusive. A study in mouse models of myocardial injury showed that CCL17 deficiency increased Treg recruitment to the heart and attenuated myocardial inflammation and injury, which may be attributed to the cancellation of competitive inhibition of CCL22-mediated Treg chemotaxis by CCL17 (<xref ref-type="bibr" rid="bib9">Feng et al., 2022</xref>), suggesting that CCL17 may impair Treg homeostasis via the inhibition of the CCL22–CCR4 axis. Given the crucial role of the CCL22–CCR4 axis in mediating the Treg suppressive function described above (<xref ref-type="bibr" rid="bib24">Rapp et al., 2019</xref>), we propose that the CCL22–CCR4 axis plays a dominant role in the prevention of atherosclerosis by promoting Treg function, which may be inhibited by stimulating the CCL17–CCR4 axis. However, the specific roles of the CCL17–CCR4 and CCL22–CCR4 axes in the various stages of atherosclerosis have not been fully elucidated, and further studies are needed.</p><p>This study has several limitations. In flow cytometric analysis, we did not exclude dead cells or doublets. This procedure could have increased the reliability of our data. Although Treg transfer experiments revealed a critical role for CCR4 in Tregs in protecting against early atherosclerosis, the use of conditional knockout mice would provide additional definitive evidence. Our data were obtained from animal experiments, and investigations using human samples will be needed to translate our findings to clinical settings.</p><p>In conclusion, we demonstrated that CCR4 protects against early atherosclerosis by favorably modulating the balance between proatherogenic Th1 cell responses and atheroprotective Treg responses. We showed that CCR4 expression on Tregs is critical for suppressing Th1 cell responses and may play an important role in mediating Treg migration to the atherosclerotic aorta. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Animals</title><p>All mice were male on a C57BL/6 background and fed a standard chow diet or a high-cholesterol diet containing 1.25% cholesterol (CLEA Japan, Tokyo, Japan) as indicated. Wild-type mice were obtained from CLEA Japan. <italic>Apoe</italic><sup>-/-11</sup> and <italic>Ccr4</italic><sup>-/-</sup> mice (<xref ref-type="bibr" rid="bib20">Matsuo et al., 2016</xref>) are previously described. We crossed <italic>Ccr4</italic><sup>-/-</sup> mice with <italic>Apoe</italic><sup>-/-</sup> mice to obtain <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Kaede-Tg mice (RBRC05737) (<xref ref-type="bibr" rid="bib36">Tomura et al., 2008</xref>) were provided by the RIKEN BRC through the National BioResource Project of the MEXT/AMED, Japan. We housed mice in cages for each strain or treatment group in a specific pathogen-free animal facility at Kobe Pharmaceutical University. Randomization and allocation concealment were performed. Littermate mice of each genotype were randomly allocated to each experimental group. During the experiments, animal/cage location was not controlled. The investigators were not blinded to the mouse genotype or treatment allocation. The criterion for exclusion was defined as severe body weight loss and set before the study. However, during at least two observations per week, we did not find such symptoms, and no mice were excluded. The experimental procedures were performed in our laboratory rooms or animal facility. All animal experiments were approved by the Animal Care Committee of Kobe Pharmaceutical University (permit numbers: 2018-008, 2019-011, 2020-050, 2021-038, 2022-005, 2023-038, and 2024-014) and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments).</p></sec><sec id="s4-2"><title>Assessment of biochemical parameters</title><p>Under anesthesia by intraperitoneal injection of medetomidine hydrochloride (0.3 mg/kg), midazolam (4 mg/kg), and butorphanol tartrate (5 mg/kg) (all from WAKO, Osaka, Japan), blood was collected by the cardiac puncture after overnight fasting, and plasma lipid profile was analyzed as described previously (<xref ref-type="bibr" rid="bib33">Tanaka et al., 2024</xref>). Concentrations of plasma total cholesterol, high-density lipoprotein-cholesterol, and triglycerides were determined enzymatically using an automated chemistry analyzer (Oriental Yeast Co., Ltd., Tokyo, Japan).</p></sec><sec id="s4-3"><title>Assessment of atherosclerotic lesions</title><p>The atherosclerotic lesions in the aortic root and thoracoabdominal aorta were analyzed as described previously (<xref ref-type="bibr" rid="bib33">Tanaka et al., 2024</xref>). For analysis of atherosclerotic lesions in the aortic root, five consecutive sections (10 μm thickness), spanning 600 μm of the aortic sinus (150 μm interval), were collected from each mouse and stained with hematoxylin-eosin. The lesion area of the sections was quantified using ImageJ (National Institutes of Health). Some sections were stained with Oil Red O (Sigma) for representative photomicrographs of the aortic sinus atherosclerotic lesions. For en face analysis of thoracoabdominal aortas, the aorta was opened longitudinally and stained with Oil Red O. The proportion of the lesion area was determined using ImageJ.</p></sec><sec id="s4-4"><title>Histological analysis of atherosclerotic lesions</title><p>Immunofluorescence staining of CCL17 and CCL22 in lymphoid tissues and atherosclerotic lesions was performed on 4% paraformaldehyde-fixed cryosections of mouse aortic roots using rabbit anti-CCL17 (1:200; abcam) or goat anti-CCL22 (1:200; R&amp;D Systems) antibodies, followed by detection with fluorescent secondary antibodies. For costaining of macrophages in the above cryosections, anti-MOMA-2 (1:400; BMA Biomedicals) and fluorescent secondary antibodies were also used. Stained sections were digitally captured using a fluorescence microscope (BZ-X810; KEYENCE, Osaka, Japan).</p><p>For the detection of macrophages or CD4<sup>+</sup> T cells, immunohistochemistry was performed on 4% paraformaldehyde-fixed cryosections of mouse aortic roots using anti-MOMA-2 or anti-CD4 (1:100; BD Biosciences) antibodies, followed by detection with biotinylated secondary antibodies and streptavidin-horseradish peroxidase. Staining with Masson’s trichrome (Muto Pure Chemicals, Tokyo, Japan) was used to delineate the fibrous area. Stained sections were digitally captured using a microscope (BZ-X810; KEYENCE), and the percentage of the stained area (the stained area per total atherosclerotic lesion area) was calculated as described previously (<xref ref-type="bibr" rid="bib28">Sasaki et al., 2009</xref>). CD4<sup>+</sup> T cells were quantified as described previously by counting the number of positively stained cells, which was divided by the total plaque area (<xref ref-type="bibr" rid="bib28">Sasaki et al., 2009</xref>). The primary and secondary antibodies used are listed in <xref ref-type="table" rid="table4">Table 4</xref>.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Antibodies for immunohistochemistry.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Antibodies</th><th align="left" valign="bottom">Clone</th><th align="left" valign="bottom">Fluorescent dye</th><th align="left" valign="bottom">Source</th></tr></thead><tbody><tr><td align="left" valign="bottom">Anti-CCL17 Ab</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">abcam</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">ab182793</td></tr><tr><td align="left" valign="bottom">Anti-MOMA-2 Ab</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">BMA Biomedical</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">T-2007</td></tr><tr><td align="left" valign="bottom">Anti-CCL22 Ab</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">R&amp;D</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">AF439</td></tr><tr><td align="left" valign="bottom">Anti-CD4 Ab</td><td align="left" valign="bottom">RM4-5</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">550280</td></tr><tr><td align="left" valign="bottom">Anti-rabbit IgG</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Alexa Fluor 568</td><td align="left" valign="bottom">Thermo Fisher Scientific</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">A11011</td></tr><tr><td align="left" valign="bottom">Anti-goat IgG</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Alexa Fluor 568</td><td align="left" valign="bottom">Thermo Fisher Scientific</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">A11057</td></tr><tr><td align="left" valign="bottom">Anti-rat IgG</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Alexa Fluor 488</td><td align="left" valign="bottom">Thermo Fisher Scientific</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">A21208</td></tr><tr><td align="left" valign="bottom">Anti-rat IgG</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Biotin</td><td align="left" valign="bottom">abcam</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">ab102250</td></tr></tbody></table></table-wrap></sec><sec id="s4-5"><title>Flow cytometry</title><p>For flow cytometric analysis of lymphoid tissues, peripheral LN cells and splenocytes were isolated and stained in PBS containing 2% fetal calf serum. For analysis of immune cells within the aorta, mice were anesthetized, and the aorta was perfused with cold saline. The aorta was dissected and the adventitial tissue was carefully removed. The aorta was digested with Liberase (Roche Diagnostics) in plain RPMI medium at 37℃ for 45 min with vortexing. For the detection of CCR4 on aortic T cells, Collagenase D (Sigma-Aldrich) was used instead of Liberase. A cell suspension obtained by mashing the aorta through a 70 μm strainer was stained with antibodies specific for CD3, CD4, CD45, CCR4, Foxp3, T-bet, RORγt, and GATA3. The Foxp3 staining buffer set (Thermo Fisher Scientific) was used for intracellular staining of Foxp3. In all staining procedures, Fc receptors were blocked by anti-CD16/CD32 (BD Biosciences). Flow cytometric analysis was performed with FACSAria III (BD Biosciences) using FlowJo software version 10.8.1 (Tree Star). The antibodies used were listed in <xref ref-type="table" rid="table5">Table 5</xref>. Gating strategy of flow cytometric analysis of aortic T cells is shown in <xref ref-type="fig" rid="app4fig1">Appendix 4—figure 1</xref>.</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Antibodies for flow cytometry.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Antibodies</th><th align="left" valign="bottom">Clone</th><th align="left" valign="bottom">Fluorescent dye</th><th align="left" valign="bottom">Source</th></tr></thead><tbody><tr><td align="left" valign="bottom">Anti-CD16/CD32 Ab</td><td align="left" valign="bottom">2.4G2</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553142</td></tr><tr><td align="left" valign="bottom">Anti-CD45 Ab</td><td align="left" valign="bottom">30-F11</td><td align="left" valign="bottom">PerCPCy5.5</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">550994</td></tr><tr><td align="left" valign="bottom">Anti-CD3 Ab</td><td align="left" valign="bottom">145-2C11</td><td align="left" valign="bottom"/><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">553066</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">553062</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">PECy7</td><td align="left" valign="bottom">552774</td></tr><tr><td align="left" valign="bottom">Anti-CD4 Ab</td><td align="left" valign="bottom">RM4-5</td><td align="left" valign="bottom">PECy7</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">552775</td></tr><tr><td align="left" valign="bottom">Anti-CCR4 Ab</td><td align="left" valign="bottom">2G12</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BioLegend</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">131204</td></tr><tr><td align="left" valign="bottom">Anti-Foxp3 Ab</td><td align="left" valign="bottom">FJK-16s</td><td align="left" valign="bottom">V450</td><td align="left" valign="bottom">eBioscience</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">48-5773-82</td></tr><tr><td align="left" valign="bottom">Anti-CD44 Ab</td><td align="left" valign="bottom">IM7</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553134</td></tr><tr><td align="left" valign="bottom">Anti-CD62L Ab</td><td align="left" valign="bottom">MEL-14</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553150</td></tr><tr><td align="left" valign="bottom">Anti-Ki67 Ab</td><td align="left" valign="bottom">SolA15</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">eBioscience</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">11-5698-82</td></tr><tr><td align="left" valign="bottom">Anti-CD152 Ab</td><td align="left" valign="bottom">UC10-4B9</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">eBioscience</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">17-1522-82</td></tr><tr><td align="left" valign="bottom">Anti-CD103 Ab</td><td align="left" valign="bottom">M290</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">557494</td></tr><tr><td align="left" valign="bottom">Anti-CD25 Ab</td><td align="left" valign="bottom">PC61</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553866</td></tr><tr><td align="left" valign="bottom">Anti-CD28 Ab</td><td align="left" valign="bottom">37.51</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553294</td></tr><tr><td align="left" valign="bottom">Anti-IFNγ Ab</td><td align="left" valign="bottom">XMG1.2</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">554412</td></tr><tr><td align="left" valign="bottom">Anti-IL-4 Ab</td><td align="left" valign="bottom">11B11</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">554435</td></tr><tr><td align="left" valign="bottom">Anti-IL-10 Ab</td><td align="left" valign="bottom">JES5-16E3</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">554468</td></tr><tr><td align="left" valign="bottom">Anti-IL-17 Ab</td><td align="left" valign="bottom">TC11-18H10</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">560184</td></tr><tr><td align="left" valign="bottom">Anti-T-bet Ab</td><td align="left" valign="bottom">4B10</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">BioLegend</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">644814</td></tr><tr><td align="left" valign="bottom">Anti-Gata3 Ab</td><td align="left" valign="bottom">L50-823</td><td align="left" valign="bottom">Alexa Fluor 488</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">560163</td></tr><tr><td align="left" valign="bottom">Anti-RORγt Ab</td><td align="left" valign="bottom">Q31-378</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">562607</td></tr><tr><td align="left" valign="bottom">Anti-CD8 Ab</td><td align="left" valign="bottom">53-6.7</td><td align="left" valign="bottom">PerCPCy5.5</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553033</td></tr><tr><td align="left" valign="bottom">Anti-B220 Ab</td><td align="left" valign="bottom">RA3-6B2</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553090</td></tr><tr><td align="left" valign="bottom">Anti-CD11b Ab</td><td align="left" valign="bottom">M1/70</td><td align="left" valign="bottom">V450</td><td align="left" valign="bottom">BD Horizon</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">560455</td></tr><tr><td align="left" valign="bottom">Anti-Ly6G Ab</td><td align="left" valign="bottom">1A8</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">551460</td></tr><tr><td align="left" valign="bottom">Anti-Ly6C Ab</td><td align="left" valign="bottom">AL-21</td><td align="left" valign="bottom">AOC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">560595</td></tr><tr><td align="left" valign="bottom">Anti-NK1.1 Ab</td><td align="left" valign="bottom">PK136</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">550627</td></tr><tr><td align="left" valign="bottom">Anti-CD11c Ab</td><td align="left" valign="bottom">HL3</td><td align="left" valign="bottom">V450</td><td align="left" valign="bottom">BD Horizon</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">560521</td></tr><tr><td align="left" valign="bottom">Anti-I-Ab Ab</td><td align="left" valign="bottom">AF6-120.1</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553551</td></tr><tr><td align="left" valign="bottom">Anti-CD80 Ab</td><td align="left" valign="bottom">16-10A1</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">553769</td></tr><tr><td align="left" valign="bottom">Anti-CD86 Ab</td><td align="left" valign="bottom">GL1</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">BD Biosciences</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">558703</td></tr><tr><td align="left" valign="bottom">Anti-CD279 Ab</td><td align="left" valign="bottom">29F.1A12</td><td align="left" valign="bottom">FITC</td><td align="left" valign="bottom">BioLegend</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">135213</td></tr></tbody></table></table-wrap></sec><sec id="s4-6"><title>Intracellular cytokine staining</title><p>Immune cells from lymphoid tissues were stimulated with 20 ng/mL phorbol 12-myristate 13-acetate (Sigma) and 1 mmol/L ionomycin (Sigma) for 5 hours in the presence of Brefeldin A (Thermo Fisher Scientific). Intracellular cytokine staining was performed as described previously (<xref ref-type="bibr" rid="bib33">Tanaka et al., 2024</xref>).</p></sec><sec id="s4-7"><title>Cytokine assay</title><p>In cell culture experiments, RPMI 1640 medium (Sigma) supplemented with 10% fetal calf serum, 50 μmol/L 2β-mercaptoethanol, and antibiotics was used. The production of several major cytokines from CD4<sup>+</sup> T cells was examined as described previously (<xref ref-type="bibr" rid="bib19">Matsumoto et al., 2016</xref>). Splenic CD4<sup>+</sup> T cells (1×10<sup>5</sup> cells) isolated using MACS (Miltenyi Biotec) were stimulated with plate-bound anti-CD3 (10 µg/mL, clone 145-2C11; BD Biosciences) and soluble anti-CD28 antibodies (2 µg/mL, clone 37.51; BD Biosciences) in 96-well round-bottomed plates for 48 hours. The concentrations of IL-4, IL-10, IL-17, and IFN-γ in culture supernatants were determined by ELISA using paired antibodies specific for corresponding cytokines (R&amp;D Systems). The levels of multiple inflammation-associated cytokines and chemokines in culture supernatants were determined using a Mouse Cytokine Array Kit according to the manufacturer’s instructions (R&amp;D Systems).</p><p>In some experiments, CD4<sup>+</sup>CD25<sup>+</sup> Tregs and CD4<sup>+</sup>CD25<sup>-</sup> T cells were purified from the peripheral LNs and spleen of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice using a CD4<sup>+</sup>CD25<sup>+</sup> Regulatory T Cell Isolation Kit (Miltenyi Biotec) and anti-CD4 beads (Miltenyi Biotec) according to the manufacturer’s instructions. The purity of each population was &gt;95% and most of the CD4<sup>+</sup>CD25<sup>+</sup> T cells expressed Foxp3, as determined by flow cytometric analysis. The viability of each cell population was analyzed using 7-amino-actinomycin D (BD Biosciences) and Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit (Thermo Fisher Scientific). The detailed data are shown in <xref ref-type="fig" rid="app5fig1">Appendix 5—figure 1A–D</xref>. CD11c<sup>+</sup> DCs were isolated from spleen of <italic>Apoe</italic><sup>-/-</sup> mice treated with Liberase using MACS (Miltenyi Biotec). The purity of the CD11c<sup>+</sup> population was approximately 93%, as determined by flow cytometric analysis. CD4<sup>+</sup>CD25<sup>-</sup> T cells (1×10<sup>5</sup> cells) from <italic>Apoe</italic><sup>-/-</sup> mice and splenic CD11c<sup>+</sup> DC (2×10<sup>4</sup> cells) were cocultured with or without CD4<sup>+</sup>CD25<sup>+</sup> Tregs (1.25×10<sup>4</sup> cells) from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice in the presence of soluble anti-CD3 antibody (0.5 μg/mL) in 96-well round-bottomed plates. Culture supernatants were collected at 48 hours and analyzed by ELISA for IFN-γ as described above.</p></sec><sec id="s4-8"><title>Treg suppression assay</title><p>For analysis of the in vitro suppressive function of Tregs, CD4<sup>+</sup>CD25<sup>+</sup> Tregs and CD4<sup>+</sup>CD25<sup>-</sup> T cells were purified from pooled peripheral LNs and spleen of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice as described above. Purified CD4<sup>+</sup>CD25<sup>+</sup> Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice were cocultured with carboxyfluorescein diacetate succinimidyl ester (Thermo Fisher Scientific)-labeled CD4<sup>+</sup>CD25<sup>-</sup> conventional T cells (2.5×10<sup>4</sup> cells) from <italic>Apoe<sup>-/-</sup></italic> mice at the indicated ratios in the presence of mitomycin C (WAKO)-treated antigen-presenting cells (5×10<sup>4</sup> cells) and soluble anti-CD3 antibody (0.5 μg/mL) in 96-well round-bottomed plates. Splenocytes were used as antigen-presenting cells. The cocultured cells were maintained at 37°C with 5% CO<sub>2</sub> for 3 days. The proliferation of carboxyfluorescein diacetate succinimidyl ester-labeled CD4<sup>+</sup>CD25<sup>-</sup> conventional T cells was analyzed by flow cytometry.</p></sec><sec id="s4-9"><title>Flow cytometric analysis of DC phenotypic changes</title><p>CD4<sup>+</sup>CD25<sup>+</sup> Tregs and CD4<sup>+</sup>CD25<sup>-</sup> T cells were purified from peripheral LNs and spleen of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, and CD11c<sup>+</sup> DCs were isolated from the spleen of <italic>Apoe</italic><sup>-/-</sup> mice as described above. CD4<sup>+</sup>CD25<sup>-</sup> T cells (5×10<sup>4</sup> cell) from <italic>Apoe</italic><sup>-/-</sup> mice or a mixture of CD4<sup>+</sup>CD25<sup>+</sup> Tregs (5×10<sup>4</sup> cells) from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice and CD4<sup>+</sup>CD25<sup>-</sup> T cells (5×10<sup>4</sup> cells) from <italic>Apoe</italic><sup>-/-</sup> mice were cocultured with splenic CD11c<sup>+</sup> DCs (4×10<sup>4</sup> cells) in the presence of soluble anti-CD3 antibody (0.1 μg/mL) in 96-well round-bottomed plates. After 48 hours of coculture, the cells were collected, stained with antibodies specific for IAb, CD11c, CD80, CD86, and 7-amino-actinomycin D, and analyzed using FACSAria III (BD Biosciences).</p></sec><sec id="s4-10"><title>Quantitative reverse transcription PCR analysis</title><p>Using TRIzol reagent (Thermo Fisher Scientific), we extracted total RNA from aorta which was perfused with cold saline and subsequently soaked in RNA later (Thermo Fisher Scientific). After the isolation of CD4<sup>+</sup>CD25<sup>+</sup> Tregs and CD4<sup>+</sup>CD25<sup>-</sup> T cells as described above, we extracted total RNA from the cells using an RNeasy Mini Kit (QIAGEN). A PrimeScript RT reagent Kit (Takara, Shiga, Japan) was used for reverse transcription. Quantitative PCR analysis was conducted using a TB Green Ex Taq (Takara) and a StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) according to the manufacturer’s instructions. The primers used are listed in <xref ref-type="table" rid="table6">Table 6</xref>. Amplification reactions were performed in duplicate, and fluorescence curves were analyzed with the included software. GAPDH was used as an endogenous control reference.</p><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Primer sequences for quantitative reverse transcription PCR.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Forward primer sequence (5'→3')</th><th align="left" valign="bottom">Reverse primer sequence (5'→3')</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Gapdh</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TGTGTCCGTCGTGGATCTGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TTGCTGTTGAAGTCGCAGGAG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Il1b</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCAGGATGAGGACATGAGCAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GAACGTCACACACCAGCAGGTTA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Il6</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCACTTCACAAGTCGGAGGCTTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GCAAGTGCATCATCGTTGTTCATAC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Il10</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GACCAGCTGGACAACATACTGCTAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GATAAGGCTTGGCAACCCAAGTAA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Tnf</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCACCACGCTCTTCTGTCTAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGGTCTGGGCCATAGAACT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ifng</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CGGCACAGTCATTGAAAGCCTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GTTGCTGATGGCCTGATTGTC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Tbx21</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGCCTACCAGAACGCAGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AAACGGCTGGGAACAGGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Gata3</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGATGTAAGTCGAGGCCCAAG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ATTGCAAAGGTAGTGCCCGGTA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Rorc</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CACAGAGACACCACCGGACAT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CGTGCAGGAGTAGGCCACATT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Foxp3</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTCATGATAGTGCCTGTGTCCTCAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGGCCAGCATAGGTGCAAG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ctla4</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCTCTGCAAGGTGGAACTCATGTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCTAACTGCGACAAGGATCCAA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Cd103</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATGGCATTCAGTGGTCTGTGCTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CACCAAGGATCGGCAGTTCA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Tnfrsf18</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GTTCAGAACGGAAGTGGCAACA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GCTTGCAGATCTTGCACTGAGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Tgfb</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GTGTGGAGCAACATGTGGAACTCTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TTGGTTCAGCCACTGCCGTA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Cd44</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGGCACTGGCTCTGATTCTTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCCATTGCCACCGTTGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Cd69</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TGGCCCAACGCTCTTGTTC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GCCCAATCCAATGTTCCAGTTC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ccr4</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCTACAGCGGCATCTTCTTCAT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGTACGTGTGGTTGTGCTCTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ccr5</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCTAGCCAGAGGAGGTGAGACATC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCTATAGGTCGGAACTGACCCTTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ccr6</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGCAGTTACTCATGCCACCAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGAGCAGCATCCCACAGTTAAAG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ccr7</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGTGGTGGCTCTCCTTGTCATT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ACACCGACTCGTACAGGGTGTAGTC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ccr8</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGACCCACAACCTGCTGGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GACAGCGTGGACAATAGCCAGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Ccr1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGTTGGGACCTTGAACCTTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGGTAGGCTTCTGTGAAATCTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr3</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATCACCTGGTGGTGCTAGTGGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AAAGGCATAGAGCAGCGGATTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Cx3cr1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AAGCACTTGCCTCTGGTGGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGCCTCAGCAGAATCGTCATA</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-11"><title>In vivo Treg homing assay</title><p>CD4<sup>+</sup>CD25<sup>+</sup> Tregs were purified from the peripheral LNs and spleen of Apoe<sup>-/-</sup>Kaede-Tg or Ccr4<sup>-/-</sup>Apoe<sup>-/-</sup>Kaede-Tg mice as described above and were intravenously injected into recipient 18-week-old Apoe<sup>-/-</sup> mice (1×10<sup>6</sup> cells per mouse) on a high-cholesterol diet containing 1.25% cholesterol via the tail vein. At 20 hours after transfer, the Kaede<sup>+</sup> Treg proportions in the peripheral LNs, spleen, para-aortic LNs, and aorta of Apoe<sup>-/-</sup> mice were analyzed by flow cytometry. Gating strategy of flow cytometric analysis of Kaede-expressing Tregs in peripheral lymphoid tissues and aortas was shown in <xref ref-type="fig" rid="app6fig1">Appendix 6—figure 1</xref>.</p></sec><sec id="s4-12"><title>Analysis of atherosclerotic lesions in Treg-transferred mice</title><p>To clarify the role of CCR4 expression in Tregs in regulating atherosclerosis, CD4<sup>+</sup>CD25<sup>+</sup> Tregs were purified from the peripheral LNs and spleen of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice as described above and were intravenously injected into 12-week-old recipient <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice (1×10<sup>6</sup> cells per mouse) on a standard chow diet via the tail vein. The atherosclerotic lesions were analyzed 4 weeks after transfer as described above.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>Normality was assessed using the Shapiro–Wilk normality test. Two-tailed Student’s <italic>t</italic>-test, Mann–Whitney <italic>U</italic>-test, or one-sample <italic>t</italic>-test was used to detect significant differences between the two groups when appropriate. One-way ANOVA followed by Tukey’s multiple-comparisons test or two-way ANOVA followed by Tukey’s multiple-comparisons test was performed for multiple groups where appropriate. A value of p&lt;0.05 was considered statistically significant. No data were excluded from the analysis. The investigators were not blinded to the data analysis. For statistical analysis, GraphPad Prism version 9.0 (GraphPad Software Inc) was used.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The experimental procedures were performed in our laboratory rooms or animal facility. All animal experiments were approved by the Animal Care Committee of Kobe Pharmaceutical University (permit numbers: 2018-008, 2019-011, 2020-050, 2021-038, 2022-005, 2023-038, and 2024-014) and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101830-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript, appendix figures, and figure supplements.</p></sec><ack id="ack"><title>Acknowledgements</title><p>Kaede-Tg mice (RBRC05737) were provided by the RIKEN BRC through the National BioResource Project of the MEXT/AMED, Japan. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers JP21K08042 and JP24K11301 (to NS) and research grants from Pfizer Japan Inc (to YR), Astellas Pharma Inc (to YR), Novartis Pharma KK (to NS), Senshin Medical Research Foundation (to NS), and ONO Medical Research Foundation (to NS).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ait-Oufella</surname><given-names>H</given-names></name><name><surname>Salomon</surname><given-names>BL</given-names></name><name><surname>Potteaux</surname><given-names>S</given-names></name><name><surname>Robertson</surname><given-names>A-KL</given-names></name><name><surname>Gourdy</surname><given-names>P</given-names></name><name><surname>Zoll</surname><given-names>J</given-names></name><name><surname>Merval</surname><given-names>R</given-names></name><name><surname>Esposito</surname><given-names>B</given-names></name><name><surname>Cohen</surname><given-names>JL</given-names></name><name><surname>Fisson</surname><given-names>S</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name><name><surname>Klatzmann</surname><given-names>D</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Natural regulatory T cells control the development of atherosclerosis in mice</article-title><source>Nature Medicine</source><volume>12</volume><fpage>178</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nm1343</pub-id><pub-id pub-id-type="pmid">16462800</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alferink</surname><given-names>J</given-names></name><name><surname>Lieberam</surname><given-names>I</given-names></name><name><surname>Reindl</surname><given-names>W</given-names></name><name><surname>Behrens</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Hüser</surname><given-names>N</given-names></name><name><surname>Gerauer</surname><given-names>K</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name><name><surname>Reske-Kunz</surname><given-names>AB</given-names></name><name><surname>Ahmad-Nejad</surname><given-names>P</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen</article-title><source>The Journal of Experimental Medicine</source><volume>197</volume><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1084/jem.20021859</pub-id><pub-id pub-id-type="pmid">12615900</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buono</surname><given-names>C</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Stavrakis</surname><given-names>G</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Glimcher</surname><given-names>LH</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses</article-title><source>PNAS</source><volume>102</volume><fpage>1596</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409015102</pub-id><pub-id pub-id-type="pmid">15665085</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>JJ</given-names></name><name><surname>Haraldsen</surname><given-names>G</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Rottman</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Ponath</surname><given-names>P</given-names></name><name><surname>Andrew</surname><given-names>DP</given-names></name><name><surname>Warnke</surname><given-names>R</given-names></name><name><surname>Ruffing</surname><given-names>N</given-names></name><name><surname>Kassam</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells</article-title><source>Nature</source><volume>400</volume><fpage>776</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/23495</pub-id><pub-id pub-id-type="pmid">10466728</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>TN</given-names></name><name><surname>Kyaw</surname><given-names>TS</given-names></name><name><surname>Kanellakis</surname><given-names>P</given-names></name><name><surname>To</surname><given-names>K</given-names></name><name><surname>Tipping</surname><given-names>P</given-names></name><name><surname>Toh</surname><given-names>BH</given-names></name><name><surname>Bobik</surname><given-names>A</given-names></name><name><surname>Agrotis</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis</article-title><source>Circulation</source><volume>126</volume><fpage>1256</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.099044</pub-id><pub-id pub-id-type="pmid">22851544</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Döring</surname><given-names>Y</given-names></name><name><surname>van der Vorst</surname><given-names>EPC</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Neideck</surname><given-names>C</given-names></name><name><surname>Blanchet</surname><given-names>X</given-names></name><name><surname>Jansen</surname><given-names>Y</given-names></name><name><surname>Kemmerich</surname><given-names>M</given-names></name><name><surname>Bayasgalan</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>LJF</given-names></name><name><surname>Hristov</surname><given-names>M</given-names></name><name><surname>Bidzhekov</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Leberzammer</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>I</given-names></name><name><surname>Kral</surname><given-names>M</given-names></name><name><surname>Nitz</surname><given-names>K</given-names></name><name><surname>Parma</surname><given-names>L</given-names></name><name><surname>Gencer</surname><given-names>S</given-names></name><name><surname>Habenicht</surname><given-names>A</given-names></name><name><surname>Faussner</surname><given-names>A</given-names></name><name><surname>Teupser</surname><given-names>D</given-names></name><name><surname>Monaco</surname><given-names>C</given-names></name><name><surname>Holdt</surname><given-names>L</given-names></name><name><surname>Megens</surname><given-names>RTA</given-names></name><name><surname>Atzler</surname><given-names>D</given-names></name><name><surname>Santovito</surname><given-names>D</given-names></name><name><surname>von Hundelshausen</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis</article-title><source>Nature Cardiovascular Research</source><volume>3</volume><fpage>221</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/s44161-023-00413-9</pub-id><pub-id pub-id-type="pmid">39044999</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drobni</surname><given-names>ZD</given-names></name><name><surname>Alvi</surname><given-names>RM</given-names></name><name><surname>Taron</surname><given-names>J</given-names></name><name><surname>Zafar</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>SP</given-names></name><name><surname>Rambarat</surname><given-names>PK</given-names></name><name><surname>Mosarla</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Zlotoff</surname><given-names>DA</given-names></name><name><surname>Raghu</surname><given-names>VK</given-names></name><name><surname>Hartmann</surname><given-names>SE</given-names></name><name><surname>Gilman</surname><given-names>HK</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Zubiri</surname><given-names>L</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Reynolds</surname><given-names>KL</given-names></name><name><surname>Mayrhofer</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Neilan</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque</article-title><source>Circulation</source><volume>142</volume><fpage>2299</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.049981</pub-id><pub-id pub-id-type="pmid">33003973</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faustino</surname><given-names>L</given-names></name><name><surname>da Fonseca</surname><given-names>DM</given-names></name><name><surname>Takenaka</surname><given-names>MC</given-names></name><name><surname>Mirotti</surname><given-names>L</given-names></name><name><surname>Florsheim</surname><given-names>EB</given-names></name><name><surname>Guereschi</surname><given-names>MG</given-names></name><name><surname>Silva</surname><given-names>JS</given-names></name><name><surname>Basso</surname><given-names>AS</given-names></name><name><surname>Russo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulatory T cells migrate to airways via CCR4 and attenuate the severity of airway allergic inflammation</article-title><source>Journal of Immunology</source><volume>190</volume><fpage>2614</fpage><lpage>2621</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202354</pub-id><pub-id pub-id-type="pmid">23390295</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Bajpai</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>P</given-names></name><name><surname>Koenig</surname><given-names>A</given-names></name><name><surname>Bredemeyer</surname><given-names>A</given-names></name><name><surname>Lokshina</surname><given-names>I</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name><name><surname>Leuschner</surname><given-names>F</given-names></name><name><surname>Kreisel</surname><given-names>D</given-names></name><name><surname>Lavine</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CCL17 aggravates myocardial injury by suppressing recruitment of regulatory T Cells</article-title><source>Circulation</source><volume>145</volume><fpage>765</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.055888</pub-id><pub-id pub-id-type="pmid">35113652</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>DM</given-names></name><name><surname>Rahman</surname><given-names>AH</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Amir</surname><given-names>E-AD</given-names></name><name><surname>Amadori</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>NS</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Shamailova</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Remark</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>JR</given-names></name><name><surname>Pina</surname><given-names>C</given-names></name><name><surname>Faries</surname><given-names>C</given-names></name><name><surname>Awad</surname><given-names>AJ</given-names></name><name><surname>Moss</surname><given-names>N</given-names></name><name><surname>Bjorkegren</surname><given-names>JLM</given-names></name><name><surname>Kim-Schulze</surname><given-names>S</given-names></name><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Mocco</surname><given-names>J</given-names></name><name><surname>Faries</surname><given-names>P</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Giannarelli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title><source>Nature Medicine</source><volume>25</volume><fpage>1576</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0590-4</pub-id><pub-id pub-id-type="pmid">31591603</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname><given-names>DR</given-names></name><name><surname>Häkkinen</surname><given-names>T</given-names></name><name><surname>Lucas</surname><given-names>AD</given-names></name><name><surname>Liddiard</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Quinn</surname><given-names>CM</given-names></name><name><surname>Senaratne</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>FR</given-names></name><name><surname>Tyson</surname><given-names>K</given-names></name><name><surname>Boyle</surname><given-names>J</given-names></name><name><surname>Shanahan</surname><given-names>C</given-names></name><name><surname>Weissberg</surname><given-names>PL</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Ylä-Hertualla</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>21</volume><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1161/01.atv.21.6.923</pub-id><pub-id pub-id-type="pmid">11397698</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>JW</given-names></name><name><surname>Sokol</surname><given-names>CL</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chemokines and chemokine receptors: positioning cells for host defense and immunity</article-title><source>Annual Review of Immunology</source><volume>32</volume><fpage>659</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120145</pub-id><pub-id pub-id-type="pmid">24655300</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Pablo</surname><given-names>AM</given-names></name><name><surname>Jiang</surname><given-names>XC</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name><name><surname>Schindler</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>IFN-gamma potentiates atherosclerosis in ApoE knock-out mice</article-title><source>The Journal of Clinical Investigation</source><volume>99</volume><fpage>2752</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1172/JCI119465</pub-id><pub-id pub-id-type="pmid">9169506</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Yodoi</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response</article-title><source>Journal of the American Heart Association</source><volume>3</volume><elocation-id>e000719</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.113.000719</pub-id><pub-id pub-id-type="pmid">24755152</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Amin</surname><given-names>HZ</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Horibe</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Rikitake</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Depletion of Foxp3+ regulatory T cells augments CD4+ T cell immune responses in atherosclerosis-prone hypercholesterolemic mice</article-title><source>Heliyon</source><volume>8</volume><elocation-id>e09981</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e09981</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>KY</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Nabeshima</surname><given-names>A</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Sasaguri</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CCL22/Macrophage-derived chemokine expression in apolipoprotein E-deficient mice and effects of histamine in the setting of atherosclerosis</article-title><source>Journal of Atherosclerosis and Thrombosis</source><volume>22</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.5551/jat.27417</pub-id><pub-id pub-id-type="pmid">25492567</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klingenberg</surname><given-names>R</given-names></name><name><surname>Gerdes</surname><given-names>N</given-names></name><name><surname>Badeau</surname><given-names>RM</given-names></name><name><surname>Gisterå</surname><given-names>A</given-names></name><name><surname>Strodthoff</surname><given-names>D</given-names></name><name><surname>Ketelhuth</surname><given-names>DFJ</given-names></name><name><surname>Lundberg</surname><given-names>AM</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>SK</given-names></name><name><surname>Olivecrona</surname><given-names>G</given-names></name><name><surname>Zoller</surname><given-names>S</given-names></name><name><surname>Lohmann</surname><given-names>C</given-names></name><name><surname>Lüscher</surname><given-names>TF</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>1323</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1172/JCI63891</pub-id><pub-id pub-id-type="pmid">23426179</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wells</surname><given-names>AD</given-names></name><name><surname>Dorf</surname><given-names>ME</given-names></name><name><surname>Ozkaynak</surname><given-names>E</given-names></name><name><surname>Hancock</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>1037</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1084/jem.20041709</pub-id><pub-id pub-id-type="pmid">15809349</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Emoto</surname><given-names>T</given-names></name><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Yodoi</surname><given-names>K</given-names></name><name><surname>Kitano</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>K-I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Overexpression of Cytotoxic T-Lymphocyte-associated antigen-4 prevents atherosclerosis in mice</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>36</volume><fpage>1141</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.306848</pub-id><pub-id pub-id-type="pmid">27055906</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Imamura</surname><given-names>R</given-names></name><name><surname>Kawai</surname><given-names>S</given-names></name><name><surname>Nishiwaki</surname><given-names>K</given-names></name><name><surname>Oiso</surname><given-names>N</given-names></name><name><surname>Kawada</surname><given-names>A</given-names></name><name><surname>Yoshie</surname><given-names>O</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma</article-title><source>Cancer Letters</source><volume>378</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.04.039</pub-id><pub-id pub-id-type="pmid">27132989</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montane</surname><given-names>J</given-names></name><name><surname>Bischoff</surname><given-names>L</given-names></name><name><surname>Soukhatcheva</surname><given-names>G</given-names></name><name><surname>Dai</surname><given-names>DL</given-names></name><name><surname>Hardenberg</surname><given-names>G</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name><name><surname>Orban</surname><given-names>PC</given-names></name><name><surname>Kieffer</surname><given-names>TJ</given-names></name><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Verchere</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>3024</fpage><lpage>3028</lpage><pub-id pub-id-type="doi">10.1172/JCI43048</pub-id><pub-id pub-id-type="pmid">21737880</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>FS</given-names></name><name><surname>Aherrahrou</surname><given-names>Z</given-names></name><name><surname>Grasshoff</surname><given-names>H</given-names></name><name><surname>Heidorn</surname><given-names>MW</given-names></name><name><surname>Humrich</surname><given-names>JY</given-names></name><name><surname>Johanson</surname><given-names>L</given-names></name><name><surname>Aherrahrou</surname><given-names>R</given-names></name><name><surname>Reinberger</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name><name><surname>Ten Cate</surname><given-names>V</given-names></name><name><surname>Robles</surname><given-names>AP</given-names></name><name><surname>Koeck</surname><given-names>T</given-names></name><name><surname>Rapp</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>T</given-names></name><name><surname>Brachaczek</surname><given-names>L</given-names></name><name><surname>Luebber</surname><given-names>F</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Heidecke</surname><given-names>H</given-names></name><name><surname>Schulze-Forster</surname><given-names>K</given-names></name><name><surname>Dechend</surname><given-names>R</given-names></name><name><surname>Lackner</surname><given-names>KJ</given-names></name><name><surname>Pfeiffer</surname><given-names>N</given-names></name><name><surname>Ghaemi Kerahrodi</surname><given-names>J</given-names></name><name><surname>Tüscher</surname><given-names>O</given-names></name><name><surname>Schwarting</surname><given-names>A</given-names></name><name><surname>Strauch</surname><given-names>K</given-names></name><name><surname>Münzel</surname><given-names>T</given-names></name><name><surname>Prochaska</surname><given-names>JH</given-names></name><name><surname>Riemekasten</surname><given-names>G</given-names></name><name><surname>Wild</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Autoantibodies against the chemokine receptor 3 predict cardiovascular risk</article-title><source>European Heart Journal</source><volume>44</volume><fpage>4935</fpage><lpage>4949</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad666</pub-id><pub-id pub-id-type="pmid">37941454</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noels</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Koenen</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chemokines as therapeutic targets in cardiovascular disease</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>39</volume><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.312037</pub-id><pub-id pub-id-type="pmid">30760014</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Wintergerst</surname><given-names>MWM</given-names></name><name><surname>Kunz</surname><given-names>WG</given-names></name><name><surname>Vetter</surname><given-names>VK</given-names></name><name><surname>Knott</surname><given-names>MML</given-names></name><name><surname>Lisowski</surname><given-names>D</given-names></name><name><surname>Haubner</surname><given-names>S</given-names></name><name><surname>Moder</surname><given-names>S</given-names></name><name><surname>Thaler</surname><given-names>R</given-names></name><name><surname>Eiber</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Röhrle</surname><given-names>N</given-names></name><name><surname>Piseddu</surname><given-names>I</given-names></name><name><surname>Grassmann</surname><given-names>S</given-names></name><name><surname>Layritz</surname><given-names>P</given-names></name><name><surname>Kühnemuth</surname><given-names>B</given-names></name><name><surname>Stutte</surname><given-names>S</given-names></name><name><surname>Bourquin</surname><given-names>C</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><name><surname>Anz</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>1170</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1084/jem.20170277</pub-id><pub-id pub-id-type="pmid">30910796</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>MacFadyen</surname><given-names>JG</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><name><surname>Fonseca</surname><given-names>F</given-names></name><name><surname>Nicolau</surname><given-names>J</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Kastelein</surname><given-names>JJP</given-names></name><name><surname>Cornel</surname><given-names>JH</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Pella</surname><given-names>D</given-names></name><name><surname>Genest</surname><given-names>J</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Lorenzatti</surname><given-names>A</given-names></name><name><surname>Forster</surname><given-names>T</given-names></name><name><surname>Kobalava</surname><given-names>Z</given-names></name><name><surname>Vida-Simiti</surname><given-names>L</given-names></name><name><surname>Flather</surname><given-names>M</given-names></name><name><surname>Shimokawa</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Dellborg</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>PRF</given-names></name><name><surname>Troquay</surname><given-names>RPT</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><collab>CANTOS Trial Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title><source>The New England Journal of Medicine</source><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Orecchioni</surname><given-names>M</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>How the immune system shapes atherosclerosis: roles of innate and adaptive immunity</article-title><source>Nature Reviews. Immunology</source><volume>22</volume><fpage>251</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00584-1</pub-id><pub-id pub-id-type="pmid">34389841</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Mikami</surname><given-names>N</given-names></name><name><surname>Wing</surname><given-names>JB</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Ichiyama</surname><given-names>K</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regulatory T cells and human disease</article-title><source>Annual Review of Immunology</source><volume>38</volume><fpage>541</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042718-041717</pub-id><pub-id pub-id-type="pmid">32017635</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Tawa</surname><given-names>H</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>K-I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice</article-title><source>Circulation</source><volume>120</volume><fpage>1996</fpage><lpage>2005</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.863431</pub-id><pub-id pub-id-type="pmid">19884470</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Fukunaga</surname><given-names>A</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Emoto</surname><given-names>T</given-names></name><name><surname>Yodoi</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Hatakeyama</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>K</given-names></name><name><surname>Washio</surname><given-names>K</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Nishigori</surname><given-names>C</given-names></name><name><surname>Hirata</surname><given-names>K-I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>UVB exposure prevents atherosclerosis by regulating immunoinflammatory responses</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>37</volume><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308063</pub-id><pub-id pub-id-type="pmid">27765767</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffens</surname><given-names>S</given-names></name><name><surname>Burger</surname><given-names>F</given-names></name><name><surname>Pelli</surname><given-names>G</given-names></name><name><surname>Dean</surname><given-names>Y</given-names></name><name><surname>Elson</surname><given-names>G</given-names></name><name><surname>Kosco-Vilbois</surname><given-names>M</given-names></name><name><surname>Chatenoud</surname><given-names>L</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice</article-title><source>Circulation</source><volume>114</volume><fpage>1977</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.627430</pub-id><pub-id pub-id-type="pmid">17043169</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>30</volume><fpage>2495</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.110.215459</pub-id><pub-id pub-id-type="pmid">20930170</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Rikitake</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Recent advances on the role and therapeutic potential of regulatory T cells in atherosclerosis</article-title><source>Journal of Clinical Medicine</source><volume>10</volume><elocation-id>5907</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10245907</pub-id><pub-id pub-id-type="pmid">34945203</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Krisnanda</surname><given-names>A</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Amin</surname><given-names>HZ</given-names></name><name><surname>Horibe</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Iwaya</surname><given-names>M</given-names></name><name><surname>Fukunaga</surname><given-names>A</given-names></name><name><surname>Hirata</surname><given-names>K-I</given-names></name><name><surname>Rikitake</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Novel UV-B phototherapy with a light-emitting diode device prevents atherosclerosis by augmenting regulatory T-cell responses in mice</article-title><source>Journal of the American Heart Association</source><volume>13</volume><elocation-id>e031639</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.123.031639</pub-id><pub-id pub-id-type="pmid">38214259</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>HL</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells</article-title><source>Science</source><volume>284</volume><fpage>819</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1126/science.284.5415.819</pub-id><pub-id pub-id-type="pmid">10221917</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Kouz</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>DD</given-names></name><name><surname>Bertrand</surname><given-names>OF</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Pinto</surname><given-names>FJ</given-names></name><name><surname>Ibrahim</surname><given-names>R</given-names></name><name><surname>Gamra</surname><given-names>H</given-names></name><name><surname>Kiwan</surname><given-names>GS</given-names></name><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>López-Sendón</surname><given-names>J</given-names></name><name><surname>Ostadal</surname><given-names>P</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Angoulvant</surname><given-names>D</given-names></name><name><surname>Grégoire</surname><given-names>JC</given-names></name><name><surname>Lavoie</surname><given-names>M-A</given-names></name><name><surname>Dubé</surname><given-names>M-P</given-names></name><name><surname>Rhainds</surname><given-names>D</given-names></name><name><surname>Provencher</surname><given-names>M</given-names></name><name><surname>Blondeau</surname><given-names>L</given-names></name><name><surname>Orfanos</surname><given-names>A</given-names></name><name><surname>L’Allier</surname><given-names>PL</given-names></name><name><surname>Guertin</surname><given-names>M-C</given-names></name><name><surname>Roubille</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Efficacy and safety of low-dose colchicine after myocardial infarction</article-title><source>The New England Journal of Medicine</source><volume>381</volume><fpage>2497</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1912388</pub-id><pub-id pub-id-type="pmid">31733140</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomura</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>J</given-names></name><name><surname>Karasawa</surname><given-names>S</given-names></name><name><surname>Miwa</surname><given-names>Y</given-names></name><name><surname>Miyawaki</surname><given-names>A</given-names></name><name><surname>Kanagawa</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Monitoring cellular movement in vivo with photoconvertible fluorescence protein “Kaede” transgenic mice</article-title><source>PNAS</source><volume>105</volume><fpage>10871</fpage><lpage>10876</lpage><pub-id pub-id-type="doi">10.1073/pnas.0802278105</pub-id><pub-id pub-id-type="pmid">18663225</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Meiler</surname><given-names>S</given-names></name><name><surname>Döring</surname><given-names>Y</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Drechsler</surname><given-names>M</given-names></name><name><surname>Megens</surname><given-names>RTA</given-names></name><name><surname>Rowinska</surname><given-names>Z</given-names></name><name><surname>Bidzhekov</surname><given-names>K</given-names></name><name><surname>Fecher</surname><given-names>C</given-names></name><name><surname>Ribechini</surname><given-names>E</given-names></name><name><surname>van Zandvoort</surname><given-names>MAMJ</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Jelinek</surname><given-names>I</given-names></name><name><surname>Hristov</surname><given-names>M</given-names></name><name><surname>Boon</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Lutz</surname><given-names>MB</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Hieronymus</surname><given-names>T</given-names></name><name><surname>Junt</surname><given-names>T</given-names></name><name><surname>Zernecke</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>2898</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1172/JCI44925</pub-id><pub-id pub-id-type="pmid">21633167</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Habenicht</surname><given-names>AJR</given-names></name><name><surname>von Hundelshausen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond</article-title><source>European Heart Journal</source><volume>44</volume><fpage>2672</fpage><lpage>2681</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad304</pub-id><pub-id pub-id-type="pmid">37210082</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkels</surname><given-names>H</given-names></name><name><surname>Meiler</surname><given-names>S</given-names></name><name><surname>Lievens</surname><given-names>D</given-names></name><name><surname>Engel</surname><given-names>D</given-names></name><name><surname>Spitz</surname><given-names>C</given-names></name><name><surname>Bürger</surname><given-names>C</given-names></name><name><surname>Beckers</surname><given-names>L</given-names></name><name><surname>Dandl</surname><given-names>A</given-names></name><name><surname>Reim</surname><given-names>S</given-names></name><name><surname>Ahmadsei</surname><given-names>M</given-names></name><name><surname>Hartwig</surname><given-names>H</given-names></name><name><surname>Holdt</surname><given-names>LM</given-names></name><name><surname>Hristov</surname><given-names>M</given-names></name><name><surname>Megens</surname><given-names>RTA</given-names></name><name><surname>Schmitt</surname><given-names>MM</given-names></name><name><surname>Biessen</surname><given-names>EA</given-names></name><name><surname>Borst</surname><given-names>J</given-names></name><name><surname>Faussner</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Lutgens</surname><given-names>E</given-names></name><name><surname>Gerdes</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice</article-title><source>European Heart Journal</source><volume>38</volume><fpage>3590</fpage><lpage>3599</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx517</pub-id><pub-id pub-id-type="pmid">29045618</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkels</surname><given-names>H</given-names></name><name><surname>Ehinger</surname><given-names>E</given-names></name><name><surname>Vassallo</surname><given-names>M</given-names></name><name><surname>Buscher</surname><given-names>K</given-names></name><name><surname>Dinh</surname><given-names>HQ</given-names></name><name><surname>Kobiyama</surname><given-names>K</given-names></name><name><surname>Hamers</surname><given-names>AAJ</given-names></name><name><surname>Cochain</surname><given-names>C</given-names></name><name><surname>Vafadarnejad</surname><given-names>E</given-names></name><name><surname>Saliba</surname><given-names>A-E</given-names></name><name><surname>Zernecke</surname><given-names>A</given-names></name><name><surname>Pramod</surname><given-names>AB</given-names></name><name><surname>Ghosh</surname><given-names>AK</given-names></name><name><surname>Anto Michel</surname><given-names>N</given-names></name><name><surname>Hoppe</surname><given-names>N</given-names></name><name><surname>Hilgendorf</surname><given-names>I</given-names></name><name><surname>Zirlik</surname><given-names>A</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry</article-title><source>Circulation Research</source><volume>122</volume><fpage>1675</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.312513</pub-id><pub-id pub-id-type="pmid">29545366</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshie</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CCR4 as a therapeutic target for cancer immunotherapy</article-title><source>Cancers</source><volume>13</volume><elocation-id>5542</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13215542</pub-id><pub-id pub-id-type="pmid">34771703</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Bromley</surname><given-names>SK</given-names></name><name><surname>Means</surname><given-names>TK</given-names></name><name><surname>Jones</surname><given-names>KJ</given-names></name><name><surname>Hayashi</surname><given-names>F</given-names></name><name><surname>Bhan</surname><given-names>AK</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CCR4-dependent regulatory T cell function in inflammatory bowel disease</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>1327</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1084/jem.20062076</pub-id><pub-id pub-id-type="pmid">17548518</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>C-C chemokine receptor 4 (CCR4) is predominantly expressed on CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs.</title><p>(<bold>A–C</bold>), The graphs represent the proportions of CCR4<sup>+</sup> cells in CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs in the peripheral lymph nodes (LNs) (<bold>A</bold>), spleen (<bold>B</bold>), and para-aortic LNs (<bold>C</bold>) of 18-week-old wild-type, <italic>Apoe</italic><sup>-/-</sup>, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice assessed by flow cytometry. n=5 per group. Data points represent individual animals. Horizontal bars represent means. Error bars indicate s.d. (<bold>D</bold>) Representative flow cytometric analysis of CCR4 expression in aortic CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD4<sup>+</sup>Foxp3<sup>-</sup> non-Tregs from 18-week-old <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Pooled aortic lymphoid cells from 7 to 8 mice in each group were used. Data are representative of two independent experiments. *p&lt;0.05, **p&lt;0.01; two-way ANOVA followed by Tukey’s multiple-comparisons test: (<bold>A</bold>, <bold>B</bold> and <bold>C</bold>).</p><p><supplementary-material id="app1fig1sdata1"><label>Appendix 1—figure 1—source data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-101830-app1-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-app1-fig1-v1.tif"/></fig></app><app id="appendix-2"><title>Appendix 2</title><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>CCL17 and CCL22 are detected in peripheral lymph nodes (LNs).</title><p>Immunostaining for CCL17 (green) (<bold>A</bold>) and CCL22 (green) (<bold>B</bold>) in the peripheral LNs of 18-week-old wild-type, <italic>Apoe</italic><sup>-/-</sup>, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Nuclei were stained with DAPI (blue). Data are representative of five mice analyzed in each group. White bars represent 25 μm as described.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-app2-fig1-v1.tif"/></fig></app><app id="appendix-3"><title>Appendix 3</title><fig id="app3fig1" position="float"><label>Appendix 3—figure 1.</label><caption><title>CCL17 and CCL22 are detected in atherosclerotic lesions.</title><p>Immunostaining for CCL17 (red) and MOMA-2 (green) (<bold>A</bold>) and for CCL22 (red) and MOMA-2 (green) (<bold>B</bold>) in the aortic sinus of 18-week-old wild-type, <italic>Apoe</italic><sup>-/-</sup>, or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Boxed area is expanded to show high-power fields. Nuclei were stained with DAPI (blue). Dashed lines demarcate atherosclerotic lesions or indicate the inner lining of arteries; L, lumen. Data are representative of five mice analyzed in each group. White bars represent 50 or 200 μm as described.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-app3-fig1-v1.tif"/></fig></app><app id="appendix-4"><title>Appendix 4</title><fig id="app4fig1" position="float"><label>Appendix 4—figure 1.</label><caption><title>Gating strategy of flow cytometric analysis of T-bet, GATA3, RORγt, and Foxp3 expression in aortic CD3<sup>+</sup>CD4<sup>+</sup>CD45<sup>+</sup> T cells.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-app4-fig1-v1.tif"/></fig></app><app id="appendix-5"><title>Appendix 5</title><fig id="app5fig1" position="float"><label>Appendix 5—figure 1.</label><caption><title>The purity and viability of CD4<sup>+</sup>CD25<sup>+</sup> Tregs and CD4<sup>+</sup>CD25 T cells isolated from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice.</title><p>Representative flow cytometric analysis of CD25 and Foxp3 expression in CD4<sup>+</sup>CD25<sup>+</sup> Tregs (<bold>A</bold>) and CD4<sup>+</sup>CD25<sup>-</sup> T cells (<bold>B</bold>) purified from peripheral lymphoid tissues of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Representative flow cytometric analysis of the viability of CD4<sup>+</sup>CD25<sup>+</sup> Tregs (<bold>C</bold>) and CD4<sup>+</sup>CD25<sup>-</sup> T cells (<bold>D</bold>) purified from peripheral lymphoid tissues of <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. T cells which neither expressed 7-AAD nor Annexin V were considered viable.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-app5-fig1-v1.tif"/></fig></app><app id="appendix-6"><title>Appendix 6</title><fig id="app6fig1" position="float"><label>Appendix 6—figure 1.</label><caption><title>Gating strategy of flow cytometric analysis of Kaede-expressing Tregs in peripheral lymphoid tissues and aortas.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-app6-fig1-v1.tif"/></fig></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101830.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Escande</surname><given-names>Carlos</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dpm2z73</institution-id><institution>Institut Pasteur de Montevideo</institution></institution-wrap><country>Uruguay</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> study provides in vivo evidence that CCR4 regulates the early inflammatory response during atherosclerotic plaque formation. The authors propose that altered T-cell response plays a role in this process, shedding light on mechanisms that may be of interest to medical biologists, biochemists, cell biologists, and immunologists. The work is currently considered <bold>incomplete</bold> pending textual changes and the inclusion of proper controls.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101830.4.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Tanaka et al. investigated the role of CCR4 in early atherosclerosis, focusing on the immune modulation elicited by this chemokine receptor under hypercholesterolemia. The study found that Ccr4 deficiency led to qualitative changes in atherosclerotic plaques, characterized by an increased inflammatory phenotype. The authors further analyzed the CD4 T cell immune response in para-aortic lymph nodes and atherosclerotic aorta, showing an increase mainly in Th1 cells and the Th1/Treg ratio in Ccr4-/-Apoe-/- mice compared to Apoe-/- mice. They then focused on Tregs, demonstrating that Ccr4 deficiency impaired their immunosuppressive function in in vitro assays. Authors also states that Ccr4-deficient Tregs had, as expected, impaired migration to the atherosclerotic aorta. Adoptive cell transfer of Ccr4-/- Tregs to Apoe-/- mice mimicked early atherosclerosis development in Ccr4-/-Apoe-/- mice. Therefore, this work shows that CCR4 plays an important role in early atherosclerosis but not in advanced stages.</p><p>Strengths:</p><p>Several in vivo and in vitro approaches were used to address the role of CCR4 in early atherosclerosis. Particularly, through the adoptive cell transfer of CCR4+ or CCR4- Tregs, the authors aimed to demonstrate the role of CCR4 in Tregs' protection against early atherosclerosis.</p><p>Weaknesses:</p><p>Flow cytometry experiments are not well controlled. Dead cells and doublets were not excluded from analysis.</p><p>Clinical relevance is unclear.</p><p>Comments on revisions:</p><p>I thank the authors for addressing my suggestions.</p><p>I understand that excluding dead cells would require repeating the entire experiment. However, the authors can at least exclude doublets from the existing flow cytometry data.</p><p>I also agree with the more cautious claim regarding the role of CCR4 in Treg migration.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101830.4.sa2</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary</p><p>Tanaka and colleagues addressed the role of the C-C chemokine receptor 4 (CCR4) in early atherosclerotic plaque development using ApoE-deficient mice on a standard chow diet as a model. Because several CD4+ T cell subsets express CCR4, they examined whether CCR4-deficiency alters the immune response mediated by CD4+ T cells. By histological analysis of aortic lesions, they demonstrated that the absence of CCR4 promoted the development of early atherosclerosis, with heightened inflammation linked to increased macrophages and pro-inflammatory CD4+ T cells, along with reduced collagen content. Flow cytometry and mRNA expression analysis for identifying CD4+ T cell subsets showed that CCR4 deficiency promoted higher proliferation of pro-inflammatory effector CD4+ T cells in peripheral lymphoid tissues and accumulation of Th1 cells in the atherosclerotic lesions. Interestingly, the increased pro-inflammatory CD4+ T cell response occurred despite the expansion of T CD4+ Foxp3+ regulatory cells (Tregs), found in higher numbers in lymphoid tissues of CCR4-deficient mice, suggesting that CCR4 deficiency interfered with Treg's regulatory actions. The findings contrast with earlier studies in a murine model of advanced atherosclerosis, where CCR4 deficiency did not alter the development of the aortic lesions. The authors included a thoughtful discussion about hypothetical mechanisms explaining these contrasting results, including putative differences in the role played by the CCL17/CCL22-CCR4 axis along the stages of atherosclerosis development in this murine model.</p><p>Major strengths</p><p>• Demonstration of CCR4 deficiency's impact on early atherosclerosis. CCR4 deficiency effects on the early atherosclerosis development in the Apoe-/-mice model were demonstrated by a quantitative analysis of the lesion area, inflammatory cell content and the expression profile of several pro- and anti-inflammatory markers.</p><p>• Analysis of the T CD4+ response in various lymphoid tissues (peripheral and para-aortic lymph nodes and spleen) and the atherosclerotic aorta during the early phase of atherosclerosis in the Apoe-/-mice model. This analysis, combining flow cytometry and mRNA expression, showed that CCR4 deficiency enhanced T CD4+ cell activation, favouring the amplification of the typical biased Th1-mediated inflammatory response observed in the lymphoid tissues of hypercholesterolemic mice.</p><p>• Treg transference experiments. Transference of Treg from Apoe-/- or Ccr4-/- Apoe-/- mice to Apoe-/- mice under a standard chow diet was useful for addressing the relevance of CCR4 expression on Tregs for the atheroprotective effect of this regulatory T cell subset during early atherosclerosis.</p><p>Major weaknesses</p><p>• Methodological Limitations: The controls used in the flow cytometry analysis were suboptimal, as neither cell viability nor doublets were assessed. This may have introduced artifacts, particularly when measuring less-represented cell populations within complex samples, such as in assays evaluating Treg migration to the aorta in atherosclerotic mice.</p><p>• Incomplete understanding of CCR4-Mediated Mechanisms: The mechanisms by which CCR4 regulates early inflammation and the development of atherosclerosis were not fully clarified.</p><p>I have previously addressed the study limitations and their global impact in my earlier reviews.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101830.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Toru</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe Pharmaceutical University</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Naoto</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe Pharmaceutical University</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Krisnanda</surname><given-names>Aga</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe Pharmaceutical University</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Amin</surname><given-names>Hilman Zulkifli</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe University Hospital</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Ken</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe Pharmaceutical University</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Horibe</surname><given-names>Sayo</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe Pharmaceutical University</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Matsuo</surname><given-names>Kazuhiko</given-names></name><role specific-use="author">Author</role><aff><institution>Kindai University</institution><addr-line><named-content content-type="city">Higashi-osaka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hirata</surname><given-names>Ken-ichi</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe University Graduate School of Medicine</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Takashi</given-names></name><role specific-use="author">Author</role><aff><institution>Kindai University</institution><addr-line><named-content content-type="city">Higashi-osaka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Rikitake</surname><given-names>Yoshiyuki</given-names></name><role specific-use="author">Author</role><aff><institution>Kobe Pharmaceutical University</institution><addr-line><named-content content-type="city">Kobe</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews</p><p><bold>Response to the reviewer #2 (Public review):</bold></p><p>We greatly appreciate the reviewer’s high evaluation of our paper and helpful comments and suggestions.</p><p>Regarding in vivo Treg homing assay, we did not exclude doublets and dead cells from the analysis of Kaede-expressing Tregs migrated to the aorta, which may affect the results. We described this issue as the limitation of this study in the revised manuscript. Nonetheless, we believe the reliability of our findings because we repeated this experiment three times and obtained similar results.</p><p>There is no evidence to support the clinical relevance of our findings. Future clinical research on this topic is highly desired.</p><p><bold>Response to the reviewer #3 (Public review):</bold></p><p>We greatly appreciate the reviewer’s high evaluation of our paper and helpful comments and suggestions.</p><p>Despite the controversial role of Th17 cells in atherosclerosis, we understand the possible involvement of Th17 cells and the Th1 cell/Th17 cell balance in lymphoid tissues and aortic lesions in accelerated inflammation and atherosclerosis in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice. Although we could not completely evaluate the changes in these immune responses in detail, future study may elucidate interesting mechanisms mediated by Th17 cell responses.</p><p>As the reviewer suggested, we understand that it is necessary to provide in vivo evidence for the Treg suppressive effects on DC activation. Based on the results of in vitro experiments, we described the discussion on the in vivo evidence in the revised manuscript.</p><p>We understand methodological limitations for flow cytometric analysis of immune cells in the aorta and in vivo Treg homing assay. We described this issue as the limitation of this study in the revised manuscript. Regarding in vivo Treg homing assay, we statistically re-analyzed the combined data from multiple experiments and observed a tendency toward reduction in the proportion of CCR4-deficient Kaede-expressing Tregs in the aorta of recipient <italic>Apoe</italic><sup>-/-</sup> mice, though there was no statistically significant difference in the migratory capacity of CCR4-intact or CCR4-deficient Kaede-expressing Tregs. Accordingly, we toned down our claim that CCR4 expression on Tregs plays a critical role in mediating Treg migration to the atherosclerotic aorta under hypercholesterolemia.</p><p>The reviewer requested us to evaluate aortic inflammation in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice injected with CCR4-intact or CCR4-deficient Tregs. However, we think that this experiment will provide marginal information because Treg transfer experiments in <italic>Apoe</italic><sup>-/-</sup> mice have already shown the protective role of CCR4 in Tregs against aortic inflammation and early atherosclerosis.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) #1 and #2: CD103 and CD86 expression should be discussed on the text and not only in the response to reviewer.</p></disp-quote><p>In accordance with the reviewer’s suggestion, we added a discussion on the downregulated CD103 expression in peripheral LN Tregs and upregulated CD86 expression on DCs in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice in the discussion section in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(2) #5: Authors response is not satisfactory. No gate percentage is shown. As it currently is, the difference in the number of cells shown in the figure could be due to differences in events recorded. Furthermore, the gate strategy is not thorough. Considering the very low frequency of Kaede + cells detected, it is crucial to properly exclude doublets and dead cells.</p><p>Authors reported a dramatic difference in Kaede + Tregs cells in the aorta across experiments. This could be addressed by normalization followed by appropriate statistical analysis (One sample t-test).</p><p>The data shown is not strong enough to conclude that there is a reduced migration to the aorta.</p></disp-quote><p>We understand the importance of reviewer’s suggestion. We described the percentage of Kaede+ Tregs in the aorta of <italic>Apoe</italic><sup>-/-</sup> mice receiving transfer of Kaede-expressing CCR4-intact or CCR4-deficient Tregs in Figure 5I.</p><p>As the reviewer pointed out, we understand that it would be important to properly exclude doublets and dead cells in in vivo Treg homing assay. However, it is difficult for us to resolve this issue because we need to perform the same experiments again which will require a great number of additional mice and substantial amount of time. We deeply regret that these important experimental procedures were not performed. We described this issue as the limitation of this study.</p><p>In accordance with the reviewer’s suggestion, we re-analyzed the combined data from multiple experiments using one-sample <italic>t</italic>-test. We observed a tendency toward reduction in the proportion of CCR4-deficient Kaede-expressing Tregs in the aorta of recipient <italic>Apoe</italic><sup>-/-</sup> mice, though there was no statistically significant difference in the migratory capacity of CCR4-intact or CCR4-deficient Kaede-expressing Tregs. By modifying the corresponding descriptions in the manuscript, we toned down our claim that CCR4 expression on Tregs plays a critical role in mediating Treg migration to the atherosclerotic aorta under hypercholesterolemia.</p><disp-quote content-type="editor-comment"><p>(3) #8: There are still several not shown data</p></disp-quote><p>In accordance with the reviewer’s suggestion, we showed the data on the responses of Tregs and effector memory T cells in 8-week-old wild-type or <italic>Ccr4</italic><sup>-/-</sup> mice and <italic>Ccr4</italic> mRNA expression in Tregs and non-Tregs from <italic>Apoe</italic><sup>-/-</sup> or <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice in Supplementary Figures 4 and 7.</p><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><disp-quote content-type="editor-comment"><p>(1) Issue 1. For future studies, I recommend not omitting viability controls during cell staining. Removal of dead cells and doublets should always be included during the gating strategy to avoid undesirable artefacts, especially when analysing less-represented cell populations. According to your previous report (ref #40), I agree that isotype controls were unnecessary using the same staining protocol. FMO controls should always be included in flow cytometry analysis (not mentioned in the methodology description and ref#40).</p></disp-quote><p>As the reviewer suggested, we understand that it would be important to properly exclude dead cells and doublets and to prepare FMO controls in flow cytometric analysis. We deeply regret that these important experimental procedures were not performed. We described this issue as the limitation of this study.</p><disp-quote content-type="editor-comment"><p>(2) Issue 3. Although Th17's role in atherosclerosis remains controversial, the data obtained in this work could provide valuable insights if discussed appropriately. As noted in my public review, I found it noteworthy that ROR γ <italic>t</italic>+ cells represented around 13% of effector TCD45+CD3+CD4+ lymphocytes in the aorta of <italic>Apoe</italic><sup>-/-</sup> mice while Th1 less than 5% (Fig 4H and F, respectively). I recognise that differences in cell staining sensibility and robustness for different transcription factors may influence these percentages. However, analysing how CCR4 deficiency influences the Th1/TI h17 balance would yield interesting data, similar to what was done for the Th1/Treg ratio.</p></disp-quote><p>Considering the higher proportion of Th17 cells than Th1 or Th2 cells in atherosclerotic aorta, we understand the importance of reviewer’s suggestion. However, we could not evaluate the effect of CCR4 deficiency on the Th1/Th17 balance in aorta because we did not perform flow cytometric analysis of aortic Th1 and Th17 cells in the same mice. Meanwhile, we could examine the Th1/Th17 balance in peripheral lymphoid tissues by flow cytometry. We found a significant increase in the Th1/Th17 ratio in the peripheral LNs of <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice, while there were no changes in its ratio in the spleen or para-aortic LNs of these mice, which limits the contribution of the Th1/Th17 balance to exacerbated atherosclerosis. We showed these data below.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101830-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(3) Issue 4. I appreciate the authors for sharing data on the flow cytometry analysis of Tregs in para-aortic LNs of <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup> <italic>Apoe</italic><sup>-/-</sup> mice, which would have been included as a Supplementary figure. These results reinforce the notion that Treg dysfunction in CCR4-deficient mice may not be due to the downregulation of regulatory cell surface receptors.</p></disp-quote><p>We showed the data on the expression of CTLA-4, CD103, and PD1 in Tregs in the para-aortic LNs of <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice in Supplementary Figure 8.</p><disp-quote content-type="editor-comment"><p>(4) Issue 5. I agree that CD4+ T cell responses are substantially regulated by DCs. While CD80 and CD86 on DC primarily serve as costimulatory signals for T-cell activation, cytokines secreted by DCs are primordial signals for determining the differentiation phenotype of effector Th cells. Since the analysis of DC phenotype in lymphoid tissues of <italic>Apoe</italic><sup>-/-</sup> and <italic>Ccr4</italic><sup>-/-</sup> <italic>Apoe</italic><sup>-/-</sup> mice could not be addressed in this study, it is not possible to differentiate which processes may be mainly affected by CCR4-deficiency during CD4+ T cell activation. In this scenario, and considering in vitro studies, the results suggest a possible role of CCR4 in controlling the extent of activation of CD4+T cells rather than shifting the CD4+T cell differentiation profile in peripheral lymphoid tissues, where a predominant Th1 profile was already established in <italic>Apoe</italic><sup>-/-</sup> mice. Therefore, I advise caution when concluding about shifts in CD4+ T cell responses.</p></disp-quote><p>We thank the reviewer for providing us thoughtful comments. As the reviewer pointed out, we understand that we should carefully interpret the mechanisms for the shift of CD4+ T cell responses by CCR4 deficiency.</p><disp-quote content-type="editor-comment"><p>(5) Regarding migration studies in the revised manuscript. I fully understand that Treg transference assays are challenging. The results do not suggest that CCR4 was critical for Treg migration to lymphoid tissues in the conditions assayed. Concerning migration to the aorta, I found the results inconclusive since the authors mention that: (i) there was a dramatic difference in the absolute numbers of Kaede-expressing Tregs that migrated to the aorta impairing statistical analysis; (ii) the number of Kaede-expressing Tregs that migrated to the aorta was extremely low; (iii) dead cells and doublets were not removed in the flow cytometry analysis. In this context, I do not agree with the following statements and recommend revising them:</p><p>- &quot;CCR4 deficiency in Tregs impaired their migration to the atherosclerotic aorta&quot; (lines 36-7),</p><p>- &quot;…we found a significant reduction in the proportion of CCR4 deficient Kaede-expressing Tregs in the aorta of recipient <italic>Apoe</italic><sup>-/-</sup> mice&quot; (lines 356-7),</p><p>- &quot;CCR4 expression on Tregs regulates the development of early atherosclerosis by....... mediating Treg migration to the atherosclerotic aorta&quot; (lines 409-411),</p><p>- &quot;…we found that CCR4 expression on Tregs is critical for regulating atherosclerosis by mediating their migration to the atherosclerotic aorta&quot; (lines 437-438),</p><p>- &quot;CCR4 protects against early atherosclerosis by mediating Treg migration to the aorta.... (lines 464-465),</p><p>- &quot;We showed that CCR4 expression on Tregs is critical for ...... mediating Treg migration to the atherosclerotic aorta&quot; (503-505).</p></disp-quote><p>We understand the importance of the reviewer’s suggestion. We described this issue as the limitation of this study. In accordance with the reviewer’s suggestion, we modified the above descriptions and toned down our claim that CCR4 expression on Tregs plays a critical role in mediating Treg migration to the atherosclerotic aorta under hypercholesterolemia.</p><disp-quote content-type="editor-comment"><p>(6) Line 206: Mention the increased expression of CD86 by DCs</p></disp-quote><p>We mentioned this result in the revised manuscript. We also added a discussion on the upregulated CD86 expression on DCs in <italic>Ccr4</italic><sup>-/-</sup><italic>Apoe</italic><sup>-/-</sup> mice in the discussion section in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(7) Lines 304-305. According to Fig 4F-H, a selective accumulation of Th1 cells seems to have occurred only in the aorta, coinciding with a higher Th1/Treg ratio. No selective accumulation of Th1 cells was observed in para-aortic lymph nodes. These results could be clarified.</p></disp-quote><p>We modified the above description in the revised manuscript.</p></body></sub-article></article>